HPLC enantioseparation of tramadol and its metabolites: method validation and application to environmental samples by Cátia Sofia Rodrigues Silva
  
 
 
 
 
 
 
HPLC enantioseparation of Tramadol and its 
metabolites: method validation and application 
to environmental samples 
 
 
Cátia Sofia Rodrigues Silva 
 
 
Master in Quality Control  
Faculty of Pharmacy of University of Porto 
 
 
2016 
     
 
 
 
 
 
 
 
Separação enantiomérica por HPLC do 
Tramadol e seus metabolitos: validação do 
método e aplicação em amostras ambientais 
 
Cátia Sofia Rodrigues Silva 
 
Dissertação do 2º Ciclo de Estudos  
Conducente ao Grau de Mestre em Controlo de Qualidade  
– especialização em Ambiente 
 
Trabalho realizado sob a orientação do Professor Doutor Carlos 
Manuel Magalhães Afonso e Professora Doutora Maria Elizabeth 
Tiritan 
 
2016
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De acordo com a legislação em vigor, não é permitida a reprodução de qualquer 
parte desta dissertação/tese
  
HPLC enantioseparation of tramadol and metabolites: method validation and 
application to environmental samples 
 
 I 
ACKNOWLEDGEMENTS 
I would like to thank to Prof. Dr. Carlos Afonso, my supervisor, and Prof.ª Dr.ª Maria 
Elizabeth Tiritan, my co-supervision, for all the support, patience and dedication during 
the realization of this seminar and the experimental work. Your unconditional support 
was very important to me and it was certainly a privilege to work with you and acquire all 
knowledge you have given to me.  
To Prof.ª Dr.ª Cláudia Ribeiro, to Master Alexandra Maia, PhD Student, and to Master 
Virgínia Gonçalves, Superior technical of IINFACTS, I would like to thank for all the 
support that given me in experimental work, over this year, and for all the attention and 
availability in the laboratory’s work. 
To my parents, my family and my friends which have a lot of patience for me and 
make me laugh in the certain time. Thanks for the good disposition, sharing moments, 
by listen to my lamentations and specially the friendship. Without you, everything would 
be much more difficult, I’m sure! 
To my paternal grandmother, who watches differently to this my achievement from 
the few months, my thanks for everything you gave and helped along this period of my 
life. 
To Parada WWTP, localized in Maia, thank you for cede all effluent and influential 
samples used, were undoubtedly crucial to the success of the work. 
This work was developed at Laboratory of Environmental Research 
area/Environmental and Applied Chemistry research line of the IINFACTS-CESPU.   The 
author acknowledges the financial support from PARMADRUGS-CESPU-2014. This 
research was partially supported through national funds provided by FCT – Foundation 
for Science and Technology, European Regional Development Fund (ERDF) and 
COMPETE under the projects PEst-C/MAR/LA0015/2013, PTDC/MAR-BIO/4694/2014, 
and INNOVMAR - Innovation and Sustainability in the Management and Exploitation of 
Marine Resources, reference NORTE-01-0145-FEDER-000035, Research Line 
NOVELMAR. 
 
  
HPLC enantioseparation of tramadol and metabolites: method validation and 
application to environmental samples 
     
 II 
ABSTRACT 
The presence of pollutants in the environment is of great interest since it affects the 
sustainability of the planet and is a major concern of the scientific community in recent 
decades. Many of these pollutants are chiral pharmaceuticals (CP) which are present as 
single enantiomeric forms or as a mixture of enantiomers. 
CP enantiomers having different configurations, can interact differently with the chiral 
molecules of the biological systems, and may exhibit different biological activities or be 
metabolized differently. For the same reasons enantiomers may also present different 
toxicity and eco-toxicity. 
Most of the CP in the environment occur from improper disposal of unused drugs, 
human excreta and inefficient removal by wastewater treatment plants (WWTP). In 
addition it is also important to consider the presence and effects of its metabolites in the 
environment. 
Tramadol is a chiral drug, used as racemate in the treatment of pain. It is rapidly 
absorbed and metabolized in the liver, resulting in the formation of its primary 
metabolites, N-desmethyltramadol (N-DT) and O-desmethyltramadol (O-DT). 
In this work a High Performance Liquid Chromatography with Fluorescence Detector 
(HPLC-FD) method that allows the separation of the enantiomers of Tramadol and its 
metabolites in environmental matrices is presented.  
The optimized conditions to enantioseparation of Tramadol, N-DT and O-DT were 
obtained using Lux Cellulose-4 column 150 x 4.6 mm, particle size 3 µm, in isocratic 
mode with a mixture of 0.1% diethylamine in hexane and ethanol (96:4, V:V) and a flow 
rate of 0,7 mL/min. The method was validated, showing accuracy, good selectivity, 
linearity (r2>0.99) and precision in the racemic range of 56 ng/L to 384 ng/L. The 
detection limit (DL) and the quantification limit (QL) of each enantiomer were:  8 ng/L and 
28 ng/L for Tramadol and N-DT and 20 ng/L and 56 ng/L for O-DT, respectively. The 
method was applied to the study of effluents and influents of a WWTP and compounds 
were detected in a concentration range between QL and 325.1 ng/L, in effluent samples 
and between QL and 357.9 ng/L, in influent samples. 
 
Keywords: Chiral pharmaceuticals | Tramadol | N-desmethyltramadol | O-
desmethyltramadol | Effluent of WWTP | Influent of WWTP 
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RESUMO 
A presença de poluentes no meio ambiente tem um grande interesse desde que afeta 
a sustentabilidade do planeta e tem constituído uma grande preocupação na 
comunidade cientifica nas ultimas décadas. Muitos destes poluentes são fármacos 
quirais (FQ) que estão presentes numa única forma enantiomérica ou como uma mistura 
de enantiómeros. 
Os enantiómeros de um FQ têm configurações diferentes, podem interagir de modo 
diferente com moléculas quirais dos sistemas biológicos, e podem exibir atividades 
biológicas diferentes ou serem metabolizados de maneiras distintas. Pelas mesmas 
razões os enantiómeros podem apresentar diferente toxicidade e ecotoxicidade. 
A maior parte dos FQ no ambiente é proveniente do depósito impróprio de fármacos 
não usados, excreções humanas e remoção ineficiente pelas estações de tratamento 
de águas residuais (ETAR). Para além da presença dos FQ, é importante considerar 
também os seus metabolitos e os efeitos ambientais.  
Tramadol é um fármaco quiral, comercializado como mistura racémica e utilizado no 
tratamento da dor. É rapidamente absorvido e metabolizado no fígado, resultando na 
formação de dois metabolitos primários, N-desmetiltramadol (N-DT) e O-
desmetiltramadol (O-DT). 
Neste trabalho, foi estabelecido um método para a separação e quantificação dos 
enantiómeros do Tramadol e seus metabolitos por cromatografia líquida de alta 
eficiência associada à deteção por fluorescência (HPLC-FD).  
As condições otimizadas da separação enantiomérica do Tramadol, N-DT e O-DT 
foram conseguidas usando a coluna Lux Celulose-4 150 x 4.6 mm, tamanho de partícula 
3 µm, em modo isocrático com a mistura de 0.1% de dietilamina em hexano e etanol 
(96:4, V:V), e fluxo de 0.7 mL/min. O método validado demonstrou exactidão, boa 
seletividade, linearidade (r2>0.99) e precisão num intervalo de 56 ng/L a 384ng/L da 
mistura racémica. O limite de deteção (LD) e o limite de quantificação (LQ) foram 8 ng/L 
e 28 ng/L para cada enantiómero do Tramadol e do N-DT, 20 ng/L e 56 ng/L para cada 
enantiómero do O-DT, respetivamente. O método foi aplicado no estudo de Efluentes e 
Influentes de ETAR e os compostos foram detetados num intervalo de concentração 
entre o LQ e 325.1 ng/L, para amostras de efluentes e entre o LQ e 357.9 ng/L, para 
amostras de influente. 
Palavras-chave: Fármacos Quirais | Tramadol | N-desmetiltramadol | O-
desmetiltramadol | Efluente de ETAR | Influente de ETAR 
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1.1. Pharmaceuticals in the environment 
Pharmaceuticals are an important class of pollutants due to their  increasing 
consumption and their persistence of in the environment (1). These pollutants can enter 
in the environment through various routes such as emissions from health institutions, 
industries, agriculture/aquaculture and households (Figure 1) (1-4).  
 Often, wastewater treatment plants are unable to completely remove 
pharmaceuticals and residues are discharged to surface waters and can end up in the 
drinking water, potentially causing toxic effects to aquatic organisms and humans (1).  
Many pharmaceuticals pollutants that exist in the environment are chiral and can be 
present as a single enantiomer or as enantiomeric mixtures (5). This aspect brings an 
additional environmental problem because beyond the different behavior of the 
enantiomers concerning pharmacokinetic and pharmacodynamic, the toxicological and 
ecotoxicological properties can also be different (6).  
 
Figure 1: Sources of pharmaceutical products in the environment (1) 
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1.2. Chiral Pharmaceuticals 
Pharmaceuticals are compounds used in humans or animals for medical diagnosis, 
treatment, or prevention of disease (7). To achieve the desired effects, pharmaceuticals 
interact with target-molecules which are normally chiral macromolecules, such as 
enzymes, nucleic acids or membrane-bounded proteins, mediating the biochemical and 
physiological changes in the body (6). Chiral pharmaceuticals (CP) are used in several 
areas of medicine, as enantiopure forms or as racemates (4). Enantiomers can interact 
differently with chiral receptors presenting significant differences in pharmacodynamics, 
pharmacokinetics and toxicology. 
Biological activity of CP can be accomplished in two main different manners: i. both 
enantiomers have the same activity or ii. enantiomers exhibit different activities. In the 
case of the enantiomers that can display the same activities, exist cases that one 
enantiomer are more potent than the other, one enantiomer and one enantiomer have 
less toxic effects than the other. When both enantiomers of the drug have distinct 
biological activities, the drug needs to be administrated in an enantiomerically pure form. 
Flecainide (antiarrhythmic) and fluoxetine (antidepressant), are examples of CP 
administrated as racemic mixtures, that both enantiomers having the same biological 
active. In this group are included other cardiovascular drugs (beta-blockers), agents 
widely used to the treatment of hypertension, heart failure, arrhythmias, and other 
diseases. However, there are many CP that enantiomers have different biological 
activity, one enantiomer with beneficial effects and other with hazardous adverse activity. 
Example of these drugs are ketamine, S-(+)-ketamine is an anesthetic and analgesic but 
R-(-)-ketamine is associated to hallucinations and agitation; naproxen, where S-
naproxen is used as anti-inflammatory and analgesic and R- present hepatotoxicity (4, 
8). There are also many example of CP in which the enantiomers differ in the potency of 
the activity and are commercialized as racemic mixture and as enantiomerically pure 
form. Racemic citalopram is used in the treatment of depression, but  S-(+)-citalopram 
(escitalopram) is 100 times more potent as a serotonin reuptake inhibitor as compared 
to R-(-)-citalopram. Citalopram is commercialized as racemate, and escitalopram 
marketed in the enantiomerically pure form. Omeprazole that is used in the treatment of 
dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison 
syndrome is market as racemic mixture and as enantiomerically pure form 
(esomeprazole (S-(-)-omeprazole)) (4, 8). Armodafinil (R-(-)-modafinil) that is a eugeroic 
used to treat sleep disorders (4, 8) is another example. 
 Beta-blockers, also known as β-adrenergic blocking agents, a class of CP that are 
used for the management of cardiac arrhythmias, usually one enantiomer present higher 
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potency than the other. For instances, S-(-)-propranolol is 100 times more than R-(+)-
propranolol. However, most of beta-blockers (except timolol: S- isomer) are marketed as 
racemates, such as acebutolol, atenolol, alprenolol, betaxolol, carvediol, metoprolol, 
labetalol, pindolol and sotalol (4).  
Other class of CP is propionic acid derivatives non-steroidal anti-inflammatory drugs 
(NSAID), which are used as analgesic, anti-inflammatory and anti-pyretic. Ibuprofen, 
ketoprofen, fenoprofen, are the most known NSAID of this group. Only the S-enantiomer 
of these molecules is active in order to obtain an analgesic and anti-inflammatory effect, 
and is marketed in racemic and enantiopure form (4). Table 1 shows several CP that are 
used as racemic mixture or as enantiopure forms. 
Table 1: CP that are used as racemic mixture or as enantiopure forms 
 
 
Class 
Commercialized form 
Ref. 
Racemate INN Enantiopure pharmaceutical (INN) 
Calcium channel 
blocker 
Amlodipine (S)-amlodipine (levamlodipine) (9) 
Verapamil - (10) 
- (+)-diltiazem (diltiazem) (11) 
CNS stimulant 
Amphetamine (S)-amphetamine (dextroamphetamine) (12, 13) 
Methylphenidate (R,R)-methylphenidate (dexmethylphenidate) (13) 
Anaesthetic Bupivacaine (S)-bupivacaine (levobupivacaine) (14) 
General anaesthetic Ketamine (S)-ketamine (esketamine) (14) 
Antihistaminic Cetirizine (R)-cetirizine (levocetirizine) 
(12, 13, 
15) 
Antidepressant 
Citalopram (S)-citalopram (escitalopram) 
(13, 15, 
16) 
Milnacipran (S,R)-milnacipran (levomilnacipran) (17) 
Venlafaxine - (11) 
Fluoxetine - (10) 
Serotonergic 
anorectic 
Fenfluramine (S)-fenfluramine (dexfenfluramine) 
(18) 
Beta-adrenoceptor 
agonist 
Formoterol (R,R)-formoterol (arformoterol) (19) 
Salbutamol (S)-salbutamol (levalbuterol) (12) 
- (S)- albuterol (albuterol) (10) 
NSAID 
Ibuprofen (S)-ibuprofen (dexibuprofen) (15) 
Ketoprofen (S)-ketoprofen (dexketoprofen) (15) 
- (S)-naproxen (naproxen) (11, 20) 
(INN: International Nonproprietary Name) 
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Table 1: CP that are used as racemic mixture or as enantiopure forms (continuation) 
(INN: International Nonproprietary Name) 
1.2.1. Toxicity of Chiral Pharmaceuticals  
In last two decades the impact of pharmaceuticals on aquatic organism and in the 
environment has been a growing concern due to acute and long exposure toxicity, but 
also due its genotoxicity and mutagenicity. This concern  is extended to human health 
due food chain and drinking water contamination (23). When introduced into the 
environment pharmaceuticals can affect animals that have identical target organs, 
tissues, cells or biomolecules (24).  
Class 
Commercialized form 
Ref. 
Racemate INN Enantiopure pharmaceutical (INN) 
Wakefulness-promoting Modafinil (R)-modafinil (armodafinil) (13) 
Antimicrobial Ofloxacin (S)-ofloxacin (levofloxacin) (15) 
Hypnotic Zopiclone (S)-zopiclone (eszopiclone) (13, 21) 
Analgesic 
Methadone (R)-methadone (levomethadone) (22) 
Tramadol - (11) 
- (-)-morphine (morphine) (8) (14) 
Antidiabetic Rosiglitazone - (10) 
β-blockers 
Atenolol - (8) 
Propranolol - (11) 
Metoprolol - (11) 
Anticoagulants Warfarin - (8) 
Anti-arrhythmic Flecanide - (11) 
Sedative/Hypnotics Diazepam - (11) 
Proton pump inhibitors 
Omeprazole (S)-omeprazole (esomeprazole) (12, 15) 
Pantoprazole - (11) 
Lansoprazole - (11) 
Angiotensin-II receptor 
antagonist 
- (S)- valsartan (valsartan) (11) 
- (R)- losartan (losartam) (11) 
Angiotensin-converting 
enzyme inhibitors 
- (S)- ramipril (ramipril) (11) 
Anaphylaxis - (R)- epinephrine  (epinephrine) (8) 
Anticholonergics - (-)-(S)- hyoscine  (hyoscine) (8) 
Dopaminergic 
antiparkinsinism agents 
- (S)- levodopa  (levodopa) (8) 
Antithyroid  and Thyroid 
hormone 
- (S)- levothyroxine  (levothyroxine) (8) 
Lipid regulating - (R,R)- atorvastatin (atorvastatin) (11) 
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Antibiotics are of major concern since they may lead to the development of 
antimicrobial resistance, and a threat to health. However, even anti-inflammatories have 
eco-toxicity associated with the development of visceral drop, which occurs when uric 
acid salts are deposited in organs, leading to the decline of some species populations. 
This class has also been linked to the fact cause renal dysfunction trout. Many other 
pharmaceuticals, such as chlorprozamine, fluoxetine, sertaline and propranolol,  have 
shown the ability to impact behavior and reproduction of aquatic organisms (25).   
Regarding the toxicity of CP, like the pharmacological activity the effect caused by the 
enantiomers can also differ. 
Ecotoxicological effects of CP has been studied, but only in some therapeutic 
classes and enantioselective toxicity has been poorly explored, some data are shown in 
Table 2. The enantioselective studies must be carried out more frequently and involving 
chiral drugs from different therapeutic classes for a better understanding of the toxic 
effects, as the racemic mixture may behave differently the two enantiomers. 
Table 2: Enantioselective ecotoxicological effects of CP in some species 
Class/ 
Pharmaceutial 
Specie 
(Taxonomic Group) 
Concetration Ecotoxicity effect Ref. 
Selective serotonin re-uptake inhibitors antidepressant (SSRIs) 
Fluoxetine 
Ceriodaphnia dubia 
(Crustacean) 
 (R)-FLX more toxic (26, 27) 
Daphnia magna 
(Crustacean) 
 (S)-FLX more toxic (26, 27) 
429 µg/L  (R-FLX) 
Reproduction 
[NOEC (21 d)] 
(28) 444 µg/L  (S-FLX) 
430 µg/L  (racemic) 
170 µg/L  (R-FLX) 
Reproduction 
[LOEC (21 d)] 
(28) 195 µg/L  (S-FLX) 
174 µg/L  (racemic) 
Pimephales promela 
(Fish) 
212 µg/L  (R-FLX) 
[LC50 (48 h)] (28) 216 µg/L  (S-FLX) 
198 µg/L  (racemic) 
170 µg/L  (R-FLX) Growth 
[LOEC (7 d)] (28) 51 µg/L  (S-FLX) 
53 µg/L  (racemic) 
(EC50: Effect concentration at 50% level; LC50: Lethal concentration at 50% level; LOEC: Lowest 
observed effect concentration; NOEC: No observed effect concentration) 
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Table 2: Enantioselective ecotoxicological effects of CP in some species (continuation) 
Class/ 
Pharmaceutial 
Specie 
(Taxonomic Group) 
Concetration Ecotoxicity effect Ref. 
Fluoxetine 
Pimephales promela 
(Fish) 
118 µg/L  (R-FLX) 
Growth 
[NOEC (7 d)] 
(28) 9 µg/L  (S-FLX) 
9 µg/L  (racemic) 
Paroxitine 
Daphnia magna 
(Crustacean) 
35.0 mg/L 
Immobilization* 
[EC50 (48 h)] 
(* main metabolite) 
(26) 
Cardiovascular Drugs 
β-Adrenoceptor blocking drugs 
Propranolol 
(Algae) - 
(S)-PHO is the 
most toxic 
(26) 
Ceriodaphnia dubia 
(Crustacean) 
- 
(S)-PHO is the 
most toxic 
(26, 27) 
Pimephales promela 
(Fish) 
- 
(S)-PHO affects 
the growth 
(29) 
- 
(S)-PHO is the 
most toxic 
(26, 27) 
Atenolol 
Ceriodaphnia dubia 
(Crustacean) 
- 
More sensitive to 
(S)-ATE 
(30) 
Daphnia magna 
(Crustacean) 
- 
More sensitive to 
(S)-ATE 
(30) 
 (EC50: Effect concentration at 50% level; LC50: Lethal concentration at 50% level; LOEC: Lowest 
observed effect concentration; NOEC: No observed effect concentration) 
 
1.2.2. Methods for quantification of chiral pharmaceuticals  
Quantification of CP can be performed by several analytical techniques such as gas 
and liquid chromatography, electrochemical sensors and biosensors, thin-layer 
chromatography (TLC) and even by nuclear magnetic resonance (RMN) (6). 
Enantiomers are distinguishable if and only if they are placed in a chiral environment, 
and all methods to separate or discriminate enantiomers are based on this principle. 
However for enantioselective analysis of CP in environmental matrices, chromatography 
is the most reliable methodology. 
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1.2.2.1. Liquid Chromatography 
Liquid chromatography (LC) is a technique which can operate with many types of 
detectors, such as liquid chromatography / mass spectrometry (LC/MS) and liquid 
chromatography tandem mass spectrometry (LC/MS/MS), ultraviolet-visible (UV/Vis), 
diode array, fluorescence (FD), and electrochemical. LC/MS and LC/MS/MS play an 
important role in environmental analysis, due to its versatility, sensitivity, and selectivity 
(6) being the technique most used to quantify CP in the environment. 
LC is an excellent tool for chiral analysis since there are a high number of commercial 
columns for LC able to work in different elution mode. Several different chiral columns 
are marketed for LC as Pirkle type, crown ethers, ligand exchangers, cyclodextrins, 
polysaccharides, proteins, macrocyclic antibiotics glycopeptides, among others (6). 
However mass spectrometry detection present same limitations in type of elution mode 
and the additives that can be used. 
 
1.3. Tramadol 
Tramadol [2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol] (Figure 
2), is a CP that acts as centrally acting analgesic, via an opioid mechanism and a 
nonopioid mechanisms, structurally related to codeine and morphine, used for the 
treatment of moderate to several pains (31, 32). It is a synthetic opioid that acts as 
agonist by selective activity at the µ-opioid receptors commercialized as racemic mixture 
and its major active metabolite, O-DT, shows higher affinity for the µ -opioid receptor and 
has twice the analgesic potency of the parent drug. The analgesic effect of tramadol can 
be contribution of inhibiting the reuptake of norepinephrine and serotonin, that occurs 
due the nonopioid mechanism, where predominate in (S,S)-Tramadol. The opioid 
mechanism involves (R,R)-Tramadol, that is a component opioid with weak affinity of the 
parent drug (31, 33, 34). Apart from analgesic effects, tramadol has been found to 
produce several positive effects such as antitussive, antidepressant, anti-inflammatory 
and immunostimulatory effects (35). 
It is a drug that had low incidence of adverse effects. These side effects include 
seizures, respiratory depression, nausea, vomiting, dry mouth, dizziness, fatigue, 
sweating, drowsiness, orthostatic hypotension, tiredness and constipation (31, 32, 36). 
The abuse potential is lower, but are being reported (33). The use of this CP carries 
some risks, as possible dependence, addiction and withdrawal symptoms (37). 
Tramadol in plasma, is almost (about 60 to 70%) and quickly absorbed and 
metabolized in the liver, resulting in the formation of its primary chiral metabolites, N-
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desmethyltramadol (N-DT) and O-desmethyltramadol (O-DT), represented in Figure 2, 
catalized by the cytochrome P450, mostly isoenzyme CYP2D, and further conjugation 
with glucuronic acid and sulfate, the mechanism of human metabolic pathway are 
represented in Figure 3 (37-39), in this way about 30 to 40% of the tramadol drug is 
excreted by the urine in its original form. O-DT is the main metabolite that is 
pharmacologically active and responsible for the analgesic effect of tramadol (40, 41).  
 
Figure 2: Chemical structure of enantiomers of Tramadol and of its metabolites 
 
 
Figure 3: Human Metabolic Pathway of Tramadol (37) 
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Simultaneous quantification of Tramadol and its metabolites in brain tissue of mice 
and rats (42), saliva (43), urine (43, 44), amniotic fluid (45) and plasma (39, 43, 46-58) 
as matrix with resource of different analytical techniques have been reported, using 
diverse methods (35). Quantification of the enantiomers of tramadol and its metabolites 
has also been reported. Table 3 presented a summary of the methods, that include chiral 
stationary phase (CSP) and the mobile phase used, used to quantify tramadol 
enantiomers and its metabolites by LC. 
Table 3: Methods used to separate enantiomerically and quantify enantiomers of 
tramadol and its metabolites 
Analyte CSP Detector 
Mobile Phase 
[Proportion (v/v)] 
Matrix Ref. 
Tramadol, 
N-DT and 
O-DT 
Chriralpak AD 
LC-
MS/MS 
Hex/EtOH/DEA 
[97/3/0.1] 
Human 
plasma 
(48) 
Tramadol 
and O-DT 
Lux Cellulose-2 and 
Lux Cellulose-2 
security guard column 
LC-
MS/MS 
Hex/IPA/DEA 
[90/10/0.1] 
Human 
plasma 
(59) 
Chriralpak AD 
LC-
MS/MS 
Hex/EtOH [97/3] 5 mM 
TEA 
Human 
plasma 
(60) 
Tramadol 
Chiralpack CBH 
UPLC-
MS/MS 
1mM ammonium 
acetate aqueous/MeOH 
[85/15] 
WWTP 
influent 
(61) 
Chirobiotic V 
LC-
MS/MS 
MeOH/ 0.005% Formic 
Acid/ 4mM ammonium 
Acetate 
WWTP 
samples 
(62) 
 
 
According to the literature the enantioseparation of three compounds was achieved 
by Ceccato et all.  (48) using a Chriralpak AD, a polysaccharide derivates CSP, with 
Hexane (Hex)/ Ethanol (EtOH)/Diethylamide (DEA) 97:3:0.1 (v:v:v) as mobile phase, a 
flow rate of 1 mL/min and a temperature of 25 ± 0.1 °C. This separation was achieved 
using a LC-MS/MS, this technique combine the outstanding separation of LC with the 
qualitative capabilities of Mass Spectrometry (63), which is a detector with a high 
sensitivity. The enantioseparation of each compound is presented in Figure 4, an 
Selected Reaction Monitoring (SRM) ion chromatogram, enantioseparation is achieved 
without chemoseparation. 
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Figure 4: Enantioseparation of Tramadol, N-DT and O-DT by Ceccato et all. (48) 
The methods that Chytil et all. (59) and Musshoff et all. (60) reported only achieved 
the enantioseparation of Tramadol and O-DT. Both methods use and MS detector, and 
conditions demonstrated in Table 3, both used polysaccharide derivates CSP. The 
remaining methods shown in Table 3, just separated the enantiomers of Tramadol. 
Evans et all. (62) using Chiralpack CBH CSP, an protein based CSP and Castrignano et 
all. (61) using Chirobiotic V CSP, an macrocyclic glycopeptides antibiotics CSP. 
1.3.1. Tramadol in the environment 
Tramadol has been quantified in environmental sample in the range of ng/L to g/L. 
Catrignano et al. (61) and Evans et al. (62) quantified Tramadol in samples of WWTP 
(Table 4). The metabolite O-DT has also been quantified.  
Table 4: Tramadol and its metabolite O-DT in the environmental 
Analyte Concentration (ng/L) Sample Ref. 
Tramadol 
595 ± 22 – 798 ± 39 WWTP (61) 
1320.7 ± 59.3 Influent (62) 
506.0 ± 46.6 Effluent (62) 
O-DT 801 ± 6 – 950 ± 21 WWTP (61) 
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Ecotoxicological effects of Tramadol and of its primary metabolites have already. 
Been reported (Table 5). However the eocotoxicological effects of the enantiomers has 
never been reported.  
Table 5: Ecotoxicological effects of Tramadol and of its metabolites 
Analyte 
Specie 
(Taxonomic Group) 
Concetration Ecotoxicity effect Ref. 
Tramadol (Crustacean) 
73 mg/L (racemic) [LC50 (48 h)] (63) 
130 mg/L (racemic) [LC50 (< 96 h)] (63) 
N-DT 
Vibrio Fischeri 
(Bacteria) 
10 mg/L  
Bioluminescence 
inhibition 
(41 %) 
(64) 
(LC50: Lethal concentration at 50% level) 
1.4. Objectives 
The objective of this study was to develop and validate a high performance liquid 
chromatography with fluorescence detection (HPLC-FD) methodology to separate, 
identify and quantify the enantiomers of Tramadol and its metabolites, N-DT and O-DT. 
1.4.1. Project commitments and outline of the thesis 
The understanding of the fate of Tramadol, its metabolites and transformation 
products in environmental matrices is extremely necessary to the development of 
enhanced environmental risk assessment studies. Although this matter is quite 
discussed currently in scientific research circles and is being amply studied, there are 
still important information gaps concerning CP.  
 The planning of this work had the following purposes:  
 Development and validation of an analytical HPLC-FD method for 
enantioseparation, identification and quantification of Tramadol, N-DT and O-DT. 
 Application of the developed chromatographic method to monitoring samples 
from WWTP. 
 This work is structured comprehending four main topics: introduction; material and 
methods; results and discussion and conclusions. 
HPLC enantioseparation of tramadol and metabolites: method validation and 
application to environmental samples 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2. Material and Methods 
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2.1. Instrumental conditions 
High Performance Liquid Chromatography with Fluorescence Detection (HPLC-FD) 
was used to quantification Tramadol and their primary metabolites in wastewater 
samples. 
The chromatographic equipment used in analytical analysis was a Shimadzu UFLC 
Prominence System equipped with two Pumps LC-20AD, an Autosampler SIL-20AC, 
column  oven CTO-20AC, a Degasser DGU-20A5, a System Controller CBM-20A and a 
LC Solution, Version 1.24 SP1 (Shimadzu). The Fluorescence Detector (FD) coupled to 
the LC System was a Shimadzu RF-10AXL. 
 
2.2. Standards and reagents 
Tramadol and O-DT standards were purchased from Sigma Aldrich, N-DT standard 
was purchased from Lipomed. The standards present a purity degree above 99%. 
Tramadol, N-DT and O-DT stock standard solutions were prepared at 1 mg/mL of 
racemic mixture in ethanol. These stock standard solutions were stored at -20 ºC in 
amber bottles. All the work standard solutions were obtained by dilutions of the stock 
solutions performed in appropriated solvents to analyses, accordingly to the mobile 
phase. 
The ethanol (EtOH), acetonitrile (ACN), methanol (MeOH) and propan-2-ol (IPA) 
HPLC grade were purchased from Fisher Chemical. Hexane HPLC grade was acquired 
from VWR Chemicals. Diethylamine (DEA), ammonium formate, ammonium acetate and 
ammonium trifluoroacetate (ATFA) with ≥ 99% purity were obtained from Sigma-Aldrich. 
Acetic acid was purchased by Panreac. Formic acid with 98-100% purity bought from 
MERCK. Ultrapure water was supplied by a Milli-Q water system. 
 
2.3. Enantiomeric Separation 
Standards mixture and dilution in Hex/EtOH in proportion 8:2 (v:v) and in ethanol, in 
normal elution mode and reverse elution mode, respectively were used in a final racemic 
concentration of 1 µg/mL for the optimization of the enantioseparation. 
The chiral chromatographic columns used were: Astec Chirobiotic TAG, Astec 
Chirobiotic V, Lux Cellulose-2 and Lux Cellulose-4. Astec Chirobiotic TAG and Astec 
Chirobiotic V have particle size 5 µm, with dimension of 150 x 2.1 mm, from Sulpelco 
Analytical (sigma-aldrich). Lux Cellulose-2 and Lux Cellulose-4 have particle size 3 µm, 
with dimension of 150 x 4.6 mm, from Phenomenex. Diverse mobile phases in normal, 
reversed, polar organic mode of elution, and in different flow rate were attempted (Tables 
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6, 7 and 8). The analysis was executed with an injection volume of 10 µL, a column oven 
temperature of 23 ºC and a autosampler tray temperature of 15ºC, in some cases oven 
temperature were 27 ºC. The fluorescence detector was set to an excitation wavelength 
of 275 nm and an emission wavelength of 300 nm. 
Table 6: Experimental conditions using Macrocyclic glycopeptides antibiotics CSP 
Column 
Elution 
mode 
Mobile Phase Proportion (v/v) 
Flow 
(mL/min) 
Chirobiotic 
TAG 
Normal Hex/EtOH 80/20 0.75 
Hex/EtOH 90/10 0.75 
Reversed MeOH (0.1%M ATFA) / H20  50/50 1 
MeOH (0.1%M ATFA) / H20 25/75 1 
MeOH (0.1%M ATFA) / H20 75/25 1 
ACN (0.1%M ATFA) / H20 50/50 0.5 
ACN (0.1%M ATFA) / H20 25/75 0.75 
EtOH (0.1%M ATFA) / H20 50/50 0.5 
EtOH (0.1%M ATFA) / H20 25/75 0.5 
MeOH/H20 50/50 075 
MeOH/H20 25/75 0.75 
MeOH/H20 75/25 0.75 
MeOH/H20 10/90 0.75 
Chirobiotic 
V 
Reversed EtOH/10 mM aqueous 
ammonium acetate buffer 
[pH=5.3] 
92.5/7.5 0.32 
EtOH/10 mM aqueous 
ammonium acetate buffer 
[pH=6.8] 
80/20 0.32 
EtOH/10 mM aqueous 
ammonium acetate buffer 
[pH=6.8] 
92.5/7.5 0.32 
MeOH/4 mM aqueous 
ammonium acetate buffer 
[pH=5.3] 
95/5 0.1 
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Table 7: Experimental conditions using Polysaccharide derivate Cellulose-2 CSP 
Column 
Elution 
mode 
Mobile Phase Proportion (v/v) 
Flow 
(mL/min) 
Cellulose-2 Normal Hex/IPA/DEA 90/10/0.1 0.5 
Hex/IPA/DEA 95/5/0.1 0.5 
Hex/EtOH/DEA 96/4/0.1 0.7 
Hex/EtOH/DEA 96/4/0.1 0.5 
Hex/IPA/DEA 90/10/0.1 0.5 
Hex/IPA/DEA 90/10/0.05 0.5 
Hex/IPA/DEA 96/4/0.05 0.5 
Hex/IPA/DEA 96/4/0.05 0.7* 
Hex/IPA/DEA 94/6/0.05 0.3* 
Hex/IPA/DEA 94/6/0.1 0.3* 
Reversed ACN (5 mM ammonium 
formate):DEA/H2O 35:0.1/65 0.5 
ACN (5 mM ammonium 
formate):DEA/ H2O 30:0.1/70 0.5 
ACN (5 mM ammonium 
formate):DEA/ H2O 20:0.1/80 0.7 
ACN (5 mM ammonium 
formate):DEA/ H2O 25:0.1/75 0.7 
EtOH (5 mM ammonium 
formate):DEA/ H2O 40:0.1/60 0.5 
EtOH (5 mM ammonium 
formate):DEA/ H2O 40:0.1/60 0.7* 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 16.36:28.63:0.1/55 0.5* 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 
16.36:28.63:0.05/ 
55 0.5* 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 
14.55:25.45:0.05/ 
60 0.5* 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 12.73:22.27:0.1/65 0.7* 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 14.54:25.46:0.1/60 0.5* 
ACN:EtOH ( 5mM ammonium 
formate):DEA/ H2O 8:32:0.1/60 0.5* 
(* T=27ºC) 
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Table 8: Experimental conditions using Polysaccharide derivate Cellulose-4 CSP 
Column 
Elution 
mode 
Mobile Phase Proportion (v/v) 
Flow 
(mL/min) 
Cellulose-4 Normal Hex/IPA 90/10 0.5 
Hex/IPA/DEA 90/10/0.1 0.5 
Hex/IPA/DEA 90/10/0.1 0.5* 
Hex/IPA/DEA 92/8/0.1 0.5 
Hex/IPA/DEA 94/6/0.1 0.5 
Hex/IPA/DEA 96/4/0.1 0.5 
Hex/EtOH/DEA 90/10/0.1 0.5 
Hex/EtOH/DEA 94/6/0.1 0.5 
Hex/EtOH/DEA 96/4/0.1 0.5 
Hex/EtOH/DEA 98/2/0.1 0.5 
Hex/EtOH/DEA 96/4/0.1 0.5 
Hex/EtOH/DEA 95/5/0.1 0.5 
Hex/EtOH/DEA 95/5/0.1 0.7 
Hex/EtOH/DEA 96/4/0.1 0.7 
Reversed ACN (5 mM ammonium 
formate)/ H2O:DEA (pH=8) 45/55 0.5 
ACN (5 mM ammonium 
formate)/ H2O 45/55 0.5 
H2O (20 mM  ammonium 
formate)/ACN 
pH=8 [adjusted with DEA] 
50/50 0.5 
ACN (5 mM ammonium 
formate):DEA/EtOH 50:0.1/50 0.5 
ACN (5 mM ammonium 
formate):DEA/EtOH 45:0.1/55 0.5 
H2O (20 mM ammonium 
formate) : DEA/ACN 50:0.1/50 0.5 
H2O (20 mM  ammonium 
formate) : DEA/ACN 60:0.1/40 0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 45:0.1/55 0.5 
EtOH (10 mM ammonium 
formate) : DEA/ H2O 
45:0.1/55 0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 
35:0.1/65 0.5 
(* T=27ºC)     
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Table 8: Experimental conditions using Polysaccharide derivate Cellulose-4 CSP 
(continuation) 
Column 
Elution 
mode 
Mobile Phase Proportion (v/v) 
Flow 
(mL/min) 
Cellulose-4 Reversed ACN (5 mM ammonium 
formate) : DEA/ H2O 30:0.1/70 0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 40:0.1/60 0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 50:0.1/50 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 45:0.1/55 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 45:0.1/55 0.5* 
ACN (5 mM ammonium 
formate) : DEA/ H2O 40:0.1/60 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 45:0.08/55 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 35:0.08/65 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 25:0.08/75 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 30:0.08/70 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 45:0.05/55 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 35:0.05/65 
0.5 
ACN (5 mM ammonium 
formate) : DEA/ H2O 30:0.05/70 
0.5 
EtOH (15 mM ammonium 
formate)/ H2O 
pH=8.19 [adjusted with 
DEA] 
50/50 
 
0.5 
EtOH (15 mM ammonium 
formate)/ H2O 
pH=8.03 [adjusted with 
DEA] 
40/60 
 
0.5 
EtOH (15 mM ammonium 
formate)/ H2O 
pH=7.96 [adjusted with 
DEA] 
50/50 
 
0.5 
EtOH (10 mM ammonium 
formate)/ H2O 
pH=7.96 [adjusted with 
DEA] 
50/50 
 
0.5 
(* T=27ºC) 
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Table 8: Experimental conditions using Polysaccharide derivate Cellulose-4 CSP 
(continuation) 
Column 
Elution 
mode 
Mobile Phase Proportion (v/v) 
Flow 
(mL/min) 
Cellulose-4 Reversed EtOH (10 mM ammonium 
formate)/ H2O 
pH=8.13 [adjusted with 
DEA] 
45/50 
 
0.5 
EtOH (10 mM ammonium 
formate) : DEA/ H2O 45:0.1/55 
0.5 
EtOH (10 mM ammonium 
formate) : DEA/ H2O 50:0.1/50 
0.5 
EtOH (10 mM ammonium 
formate) : DEA/ H2O 47:0.1/53 
0.5 
EtOH (10 mM ammonium 
formate) : DEA/ H2O 40:0.1/60 
0.5 
EtOH (10 mM ammonium 
formate: DEA/ H2O 50:0.1/50 
0.5 
EtOH (10 mM ammonium 
formate) : DEA/ H2O 45:0.1/55 
0.5 
MeOH (5 mM ammonium 
formate)/ H2O 45/55 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 50:0.1/50 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 45:0.1/55 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 45:0.05/55 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 60:0.05/40 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 55:0.05/45 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 45:0.05/55 
0.5 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 45:0.05/55 0.7 
MeOH (5 mM ammonium 
formate) : DEA/ H2O 45:0.02/55 
0.5 
ACN:EtOH (10 mM 
ammonium formate):DEA/ 
H2O 
20:20:0.1/65 0.5 
ACN:EtOH (10 mM 
ammonium formate):DEA/ 
H2O 
17.5:17.5:0.1/65 0.5 
ACN:EtOH (10 mM 
ammonium formate):DEA/ 
H2O 
21:9:0.1/60 0.5 
(* T=27ºC) 
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Table 8: Experimental conditions using Polysaccharide derivate Cellulose-4 CSP 
(continuation) 
Column 
Elution 
mode 
Mobile Phase 
Proportion 
(v/v) 
Flow 
(mL/min) 
Cellulose-4 Reversed ACN:EtOH (10 mM 
ammonium formate):DEA/ 
H2O 
31.5:31.5:0.1/55 0.5 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 
35:20:0.1/45 0.5 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 
28.6:14.5:0.1/55 0.5 
ACN:EtOH (5 mM ammonium 
formate):DEA/ H2O 
25.5:14.5:0.1/60 0.5 
(* T=27ºC) 
2.3.1. Calculations 
The tables of results relative to the enantiomeric separation includes values of 
retention factor (K), separation factor (α) and resolution (Rs). These parameters were 
calculated by the following formulas. 
The retention factor is calculated used the retention time of the analyte (RT) by the 
formula (1). 
(1) K = 
ோ೅ି ோ೅ బ
ோ೅ బ
~ 
(where RT 0 is the dead time of the run)  
Separation factor was calculated according to formula (2). 
(2) α = 
௄భ
௄మ
 
Resolution is represented in formula (3) and in formula (4). Formula (4) were used 
to calculate resolution.  
(3) Rs = √ே
ସ
 (ߙ − 1) ቀ ௄
ଵା௄
ቁ 
N: Theorical plates = 16 ቀோ೅
ௐ
ቁ
ଶ
  
(where W = 4 σ, is the width of the peak; σ is the standard deviation)  
 
(4) Rs =  2 × ܴܶ 1− ܴܶ 2 ൫ܹ1+ ܹ2 ൯
, w1 and w2 are the width at the base of the peaks  of the 
first and second enantiomer eluted, respectively. 
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2.4. Sample preparation 
2.4.1. Solid-phase extraction (SPE) 
Samples used to this procedure were obtained from WWTP of Parada (North of 
Portugal). The selection of the best cartridge for the SPE procedure was done by a spike 
of 200 µL of a mixture of three standards in a concentration of 1 µg/mL of the racemic 
mixture, dissolved in EtOH, in 250 mL of ultrapure water acidified with H2SO4 to pH=2, 
or basified with NaOH to pH=7.5, in the sample used to the procedure with Oasis® 
cartridge from Ireland. The cartridge used were Oasis® MCX 150 mg 6cc and Oasis® 
HLB 150 mg 6cc. 
In order to obtain a higher recovery ratio, various procedures were attempted, 
presented in Table 9, with the steps shown on Figure 5. Loading samples were done 
simultaneously using a vacuum manifold system connected to a vacuum pump and 
percolated through the cartridges at a constant flow rate of 10 mL min−1. The drying 
step, was, under vacuum for 30 min to dry out residual water and equal for all procedures. 
Elution was done in two steps, the eluate from the first step was rejected and only the 
eluated from the second step was used. In all procedures the assays were done in 
triplicate. 
 
Figure 5: Steps of SPE procedure (65) 
 
After the elution procedures, the eluted were evaporated to dryness and reconstituted 
in Hex/EtOH in the proportions of 8:2 (v:v) and 20 µL was used for the HPLC-FD 
quantification using the optimized enantioseparation method. The recovery of each 
compound is calculated by Recovery (%) = 
஺೛೐ೌೖ ೚೑ ೞ೛೔ೖ೐೏ ೞೌ೘೛೗೐ 
஺೛೐ೌೖ ೚೑ ೎೚೘೛೚ೠ೙೏ೞ ೔೙ ೞ೚೗ೡ೐೙೟
 ×  100. 
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Table 9: Experimental conditions of SPE 
Procedure Cartridge Conditioning Washing 
Elution 
(1st Step) 
Elution 
(2nd Step) 
Ref. 
1 MCX 8 mL MeOH 
8 mL H2O 
8 mL H2O 8 
mL MeOH 
8 mL 5% 
NH4OH solved 
in ACN/MeOH 
60/40 
- (66) 
2 MCX 8 mL MeOH 
8 mL H2O 
8 mL 2% 
Formic Acid 8 mL MeOH 
8 mL 
methanoic 
solution of 5% 
NH4OH 
(67) 
3 MCX 8 mL MeOH 8 mL H2O 
8 mL 2% 
Formic Acid 
12 mL 
methanoic 
solution of 10% 
NH4OH 
- (67) 
4 MCX 8 mL EtOH 
8 mL H2O 
8 mL 2% 
Formic Acid 8 mL EtOH 
8 mL ethanoic 
solution of 5% 
NH4OH 
(67) 
5 MCX 
8 mL EtOH 
8 mL Formic acid 
2% 
8 mL 2% 
Formic Acid 
 
8 mL ethanoic 
solution of 0,6 % 
of Formic Acid 
8 mL ethanoic 
solution of 5% 
NH4OH 
(68, 
69) 
6 MCX 
8 mL EtOH 
8 mL H20  (pH=2 
adjusted with HCl) 
8 mL 2% 
Formic Acid 8 mL EtOH 
8 mL ethanoic 
solution of 5% 
NH4OH 
(70) 
7 HLB 
10 mL MetOH 
10 mL H20 
10 mL H20 10 mL MeOH - (70) 
8 MCX 
8 mL MeOH 
8 mL H20 
8 mL 2% 
Formic Acid 
 
12 mL 
methanoic 
solution of 10% 
NH4OH 
- (67) 
9 MCX 8 mL EtOH 8 mL H20 
8 mL 2% 
Formic Acid 8 mL EtOH 
8 mL ethanoic 
solution of 5% 
NH4OH 
(67) 
10 MCX 
8 mL EtOH 
8 mL 2% Formic 
Acid 
8 mL 2% 
Formic Acid 
8 mL ethanoic 
solution of 0,6 % 
of Formic Acid 
12 mL 
ethanoic 
solution of 5% 
NH4OH 
(68, 
69) 
11 MCX 
8 mL EtOH 
8 mL 2% Formic 
Acid 
8 mL 2% 
Formic Acid 
12 mL ethanoic 
solution of 5% 
NH4OH 
- (68, 69) 
12 MCX 
8 mL EtOH 
8 mL 2% Formic 
Acid 
8 mL 2% 
Formic Acid 
8 mL ethanoic 
solution of 0,6 % 
of Formic Acid 
12 mL 
ethanoic 
solution of 5% 
NH4OH 
(68, 
69) 
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2.4.2. Synthetic wastewater Influent 
After optimization of the SPE procedure in ultra-pure water, the best condition was 
used to validate the method with sample of synthetic wastewater. The synthetic  
wastewater influent was preparated by the mixture of various reagents. Initially was 
preparated the Vischniac Trace element Solution, the reagents an amount used to 
prepare this solution was presented in Table 10. 
Table 10: Reagents used in preparation of Vischniac Trace Element Solution 
Reagent g/100 mL Reagent g/100 mL 
EDTA.2H2O 6.377 (NH4)6Mo7O24.4H2O 0.11 
ZnSO4.7H2O 2.2 CuSO4.5H2O 0.157 
CaCl2 0.554 CoCl2 0.0879 
MnCl2.4H2O 0.506 KOH (pellets) Adjust pH to 6 
FeSO4.7H2O 0.499   
(EDTA.2H2O: Ethylenediaminetetraacetic Acid Disodium Salt Dihydrate; ZnSO4.7H2O: Zinc Sulfate 
Heptahydrate; CaCl2: Calcium Chloride; MnCl2.4H2O: Manganese (II) Chloride Tetrahydrate; FeSO4.7H2O: 
Iron (II) Sulfate Heptahydrate; (NH4)6Mo7O24.4H2O: Ammonium Molybdate Tetrahydrate; CuSO4.5H2O: 
Copper (II) Sulfate Pentahydrate; CoCl2: Cobalt (II) Chloride; KOH: Potassium Hydroxide) 
All reagents except the KOH were weighed into a beaker and dissolved in 80 ml of 
ultrapure water. The only way of all compounds dissolve well are adjust pH to 6.0 with 
KOH pellets. The solution was poured into a 100 ml flask and made up to volume with 
water. After use the solution was stored in a refrigerator at temperature of 4 ° C for future 
use. The synthetic wasterwater was prepared with Vischniac Trace element Solution and 
another reagent mixture, which involves the substances presents in Table 11. 
Table 11: Reagents used in preparation of Synthetic wastewater 
Reagent m (g) /250 mL 
NaAc 0.121 
MgSO4.7H2O 0.021 
KCl 0.008 
Na2HPO4 0.014 
KH2PO4 0.007 
NH4Cl 0.044 
Vischniac trace elemnt solution (mL/L) 0.234 
(NaAc: Sodium Acetate; MgSO4.7H2O: Magnesium Sulfate Heptahydrate; KCl: 
Potassium Chloride; Na2HPO4: Sodium Hydrogenphosphate; KH2PO4: Potassium 
Dihydrogenphosphate; NH4Cl: Ammonium Chloride) 
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2.5. Method validation 
2.5.1. Selectivity 
Method selectivity was verified with the analysis of the synthetic wastewater matrix. A 
solution including diverse reagents, prepared as described in “2.4.2”. The matrix passed 
through a SPE procedure, dried and reconstituted in Hex/EtOH 8:2 (v:v). The resulting 
chromatogram was then compared with two others chromatograms, one referring to the 
same matrix spiked with the Tramadol, N-DT and O-DT standards in the final 
concentrations of 410 ng/mL of the racemic mixture, with the same treatment prior to 
injection, and other referring to 200 µL aliquots the mix of compounds in concentration 
of 410 ng/mL of the racemic mixture standard dried and reconstituted in Hex/EtOH 8:2 
(v:v). 
2.5.2. Linearity 
Calibration curves were performed with 200µl of a racemic mixture of seven different 
racemic concentrations (56 ng/mL, 112 ng/mL, 168 ng/mL, 224 ng/mL, 280 ng/mL, 336 
ng/mL and 384 ng/mL) spiked in 250mL acidified synthetic wasterwater. For each 
concentration, SPE procedure was processed in triplicate. The mentioned curves were 
obtained by linear regression corresponding to the correlation between the peak area 
and the nominal concentration. 
2.5.3. Accuracy  
Method accuracy was determined to each analyte using three different racemic 
concentrations (150 ng/mL, 300 ng/mL and 410 ng/mL) in a spiked matrix in triplicate 
and expressed as relative standard deviation (RSD). The protocol followed was similar 
to the one mentioned in 2.5.1. 
2.5.4. Precision  
Method precision was deliberated by the analysis of three different racemic 
concentrations (the same used in accuracy), in triplicate, of the mix of the compounds in 
spiked matrix and expressed as relative standard deviation (RSD) of intra-day (three 
determinations executed in the same day) and inter-day (three determinations executed 
in three different days) assays. 
2.5.5. Recovery  
The recovery rate of the analytical method was determined to each analyte using 
three different racemic concentrations (the same used in accuracy and precision), in 
triplicate, both in the spiked matrix and in solvent, in order to compare the 
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extraction/recovery capability of the method. The results were expressed in recovery 
percentage.  
2.5.6. Detection Limit (DL) and Quantification Limit (QL)  
Detection limit and quantification limit were determined based on signal/noise. 
Determination of signal-to-noise ratio is performed by comparing measured signals from 
samples with low concentrations of analyte with those of blank samples and establishing 
the minimum concentration at which the analyte can be reliably detected or quantified. A 
signal-to-noise ratio of 3:1 is generally acceptable to estimate the DL as a signal-to-noise 
ratio of 10:1 is typically considered to estimate the QL. 
2.6. Application of developed HPLC-FD method in WWTP samples 
The Samples were collected in 26th and 27th of June of 2016  in Parada wastewater 
treatment plant (WWTP), localized in Maia, Portugal. The samples were collected in 
influent and effluent of the WWTP, two times of day during days. 
After collection of the samples, these were filtered under vacuum and acidified with 
H2SO4 to pH=2 and preconcentrated by SPE, using a volume of sample of 250 mL, 
according to the procedures established in section 2.4.1 with injection of 20 µL. 
In order to understand if the compounds present in the samples are Tramadol, N-
DT and O-DT a crossmatch test was realized. This test consist in adding a certain 
volume, in this case 20 µL, of the mixture of the standards, with a known racemic 
concentration, 1 µg/mL, in a vial with the samples, in order to identify better what is 
compound and what is impurity. 
 
2.6.1. Calculations 
The data obtained in quantification allowed to determine the enantiomeric fraction 
(EF) and degree of removal efficiency (DRE). It is possible calculate these compounds 
trough the formula (1) and (2), respectively.  
(1) EF= ஼௢௡௖௘௡௧௥௔௧௜௢௡ ாభ/మ  
஼௢௡௖௘௡௧௥௔௧௜௢௡ ாభା ஼௢௡௖௘௡௧௥௔௧௜௢௡ ாమ
 
 
(2) DRE=஼ೌ೙ೌ೗೤೟೐ ೔೙  ೐೑೑೗ೠ೐೙೟
஼ೌ೙ೌ೗೤೟೐ ೔೙ ೔೙೑೗ೠ೐೙೟
 × 100
HPLC enantioseparation of tramadol and metabolites: method validation and 
application to environmental samples 
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3.1. Enantiomeric Separation 
Different types of chiral columns are commercial avaiable (72-76). The most important 
types of chiral selectors pointed to: Pirkle type, polysaccharide derivatives, cyclodextrin, 
protein, macrocyclic glycopeptides antibiotics-based and others based on synthetic 
polymers (72, 77, 78). The most useful and broadly applied are the CSP based on 
polysaccharide, macrocyclic antibiotics and Pirkle type (72, 75, 76, 79, 80). Due the 
versatile and suitable for all elution modes of polysaccharides or macrocyclic antibiotics 
as chiral selector many authors start the trial-error challenge with these CSP (77, 81-91). 
The range of application of polysaccharide-based CSP is broader than macrocyclic 
antibiotics-based CSP concerning the number of compounds enantioseparated by both 
CSP (75, 80, 82). In a tentative to obtain the best result of chemo and enantioseparation 
of Tramadol and its metabolites (O-DT and N-DT) CSP based on macrocyclic 
glycopeptides antibiotics and polysaccharide derivates were evaluated in normal, polar 
and reversed elution modes. 
3.1.1. Macrocyclic glycopeptides antibiotics CSP 
These CSP have a great diversity of structures which contain a variety of functional 
group, multiple stereogenic centers and inclusion cavities. These aspects show the 
success of these columns. The applicability of these CSP has  increased due the 
possibility to use  multimodal elution conditions (71). 
In the first attempted to achieve enantioseparation of Tramadol and its metabolites 
(O-DT and N-DT) macrocyclic glycopeptides antibiotics CSP, namely the Chirobiotic 
TAG (Telcoplanin Aglycone CSP) (Figure 6) was selected. This column is formed by 
covalently bonding between the aglycon part of teicoplanin and silica via linkage chains. 
This column was used in normal and reversed elution mode, the results obtain are 
represented in Table 12. 
 
Figure 6: Chemical Structure of Chirobiotic TAG (92) 
Results and Discussion 
  
 28 
Table 12: Results of enantiomeric separation of Tramadol on Chirobiotic TAG CSP 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of 
enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; Rs: Resolution; * flow rate of 0.5 
mL/min; ** flow rate of 0.75 mL/min; *** flow rate of 1 mL/min) 
 
 
Considering normal elution mode the separation of Tramadol wasn’t achieved with 
any composition of mobile phase. Due the results with normal elution mode, it decided 
change to reversed elution mode. In this elution mode, only partial enantioseparation of 
Tramadol was achieved with MeOH (0.1%M ATFA)/H2O 75:25 (v:v) as mobile phase, in 
a flow rate of 1 mL/min, a column oven in a temperature of 23 °C and with elution time 
around 7 minutes. Figure 7 presented the chromatogram of this result. The separation 
(α= 1.038) and resolution (Rs= 0.024) were not satisfactory. When the percentage of 
water was increased the elution time also increased but did not improve 
enantioseparation. . For this reason this CSP were abandoned. 
 
Analyte 
Elution 
Mode 
Mobile 
Phase 
Proportion 
(v/v) 
RT 1 
(24) 
RT 2 
(24) 
K1 K2 α Rs 
Tramadol 
Normal Hex / EtOH 80:20** 1.405 - - - 1.0 - 
Hex / EtOH 90:10** 2.058 - - - 1.0 - 
Reversed 
MeOH 
(0.1%M 
ATFA) / H2O 
50:50*** 1.483 - 1.806 - 1.0 - 
MeOH 
(0.1%M 
ATFA) / H2O 
25:75*** 1.889 - 2.638 - 1.0 - 
MeOH 
(0.1%M 
ATFA) / H2O 
75:25*** 6.786 7.009 6.749 7.003 1.038 0.024 
EtOH (0.1%M 
ATFA ) / H2O 50:50* 27.991 - 19.210 - 
1.0 - 
EtOH (0.1%M 
ATFA ) / H2O 25:75* 30.437 - 19.360 - 
1.0 - 
ACN (0.1%M 
ATFA ) / H2O 50:50* 13.273 - 8.068 - 
1.0 - 
ACN (0.1%M 
ATFA ) / H2O 25:75** 21.246 - 14.850 - 
1.0 - 
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Figure 7: Chromatogram obtain using MeOH (0.1%M ATFA)/H2O 75:25 (v:v) as mobile 
phase with Chirobiotic TAG CSP. 
Regarding Chirobiotic V (Vancomycin CSP), with  aromatic rings and peptide linkages 
that provide some rigidly to the molecule and provide good interactions with small 
molecules (Figure 8) (93). The enantioseparation of Tramadol has been reported (62). 
Several mobile phases were attempted in this CSP in order to improve the results form 
literature. The results are presented in Table 13. Several mobile phase in reversed 
elution mode were attempted and only partial enantioseparation of the enantiomers of 
N-DT was achieved (Figure 9).  
 
Figure 8: Chemical Structure of Chirobiotic V (92) 
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Table 13: Results of enantiomeric separation of Tramadol and its metabolites on 
Chirobiotic V CSP 
Analyte 
Elution 
mode 
Mobile Phase Proportion 
(v/v) 
RT 1 
(24) 
RT 2 
(24) 
K1 K2 α Rs 
Tramadol Reversed 
MeOH/4 mM aqueous 
ammonium acetate 
buffer [pH=5.3] 
95/5* >40 - - - - 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=5.3] 
92.5/7.5** 13.43 - 6.25 - 1.0 - 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=6.8] 
80/20** 9.21 - 3.88 - 1.0 - 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=6.8] 
92.5/7.5** 13.69 - 6.34 - 1.0 - 
N-DT Reversed 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=5.3] 
92.5/7.5** 23.38 24.38 11.30 11.83 1.04 0.111 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=6.8] 
92.5/7.5** 7.73 - 3.05 - 1.0  
O-DT Reversed 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=5.3] 
92.5/7.5** 14.02 - 7.67  1.0 - 
EtOH/10 mM aqueous 
ammonium acetate 
buffer [pH=6.8] 
92.5/7.5* 8.70 - 3.56 - 1.0 - 
 (RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of 
enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; Rs: Resolution; * flow rate of 0.1 
mL/min; ** flow rate of 0.32 mL/min) 
In comparison with the literature the mobile phase MeOH/4 mM aqueous ammonium 
acetate buffer [pH=5.3, adjusted with 0.005% of formic acid] (62) did not improved  the 
separate the Tramadol, and the retention time of Tramadol was superior that 40 min, 
what is an unthinkable to diary analyses. The enantioseparation of the metabolites was 
not attempted in mobile phase.  In attempted to improve the mobile conditions in order 
to achieve enantioseparation of Tramadol and its metabolites and  also to use a more 
eco-friendly solvent, ethanol with 10mM aqueous ammonium acetate buffer [pH=5.3] in 
a proportion of 92.5:7.5 (v:v) and with a flow rate of 0.1 mL/min, was attempted. Partial 
enantioseparation of N-DT was achieved, but Tramadol and O-DT did not present any 
degree of enantioseparation (Figure 9). The enantioseparation of N-DT had a poor 
resolution (Rs=0.111) and a weak separation factor (α = 1.04). The results presented in 
Table 12 and 13, led to an abandonment of this type of chiral columns in the trial and 
error. 
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Figure 9: Chromatogram using EtOH/10 mM aqueous ammonium acetate buffer 
[pH=5.3] 92.5:7.5 (v:v) and with a flow rate of 0.1 mL/min as mobile phase 
 
3.1.2. Polysaccharide derivates CSP  
Polysaccharide derivates CSP have a broad application in enantioseparation of CP 
and can be use in normal, reversed and polar elution mode, what increase the rate of 
application. The particle size (3 to 2.5 µm) allows greater speed and power of resolution 
of the column (92, 94). Chytil et all. (59) reported the enantioseparation of Tramadol and 
O-DT, using Lux Cellulose-2 CSP (Figure 10) using Hex/IPA/DEA 90:10:0.1 (v:v:v) as 
mobile phase with a flow rate of 1.3 mL/min. The first trial in this type of CSP was based 
in this report (59). The results are presented in Table 14, referring to Tramadol and the 
metabolites. 
O
OCONHR
O
OCONHR
RHNOCO
CH3
Cl
R=
 
Figure 10: Chemical Structure of Lux Cellulose-2 
The enantioseparation of Tramadol in Celullose-2 was not achieved with baseline 
resolution (Rs=1.196 and α=1.120). Tramadol with different proportion of hexane and 
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the organic modifier (ETOH or IPA) as mobile phase have a partial enantioseparation, 
with a poor resolution (Rs < 1.5). 
The enantioseparation of N-DT and O-DT, in normal phase elution mode presented, 
good results of α and Rs. The chromatograms of the best results in normal elution mode 
tested in this column are presented in Figure 11. However the enantioseparation of 
Tramadol did not presented the desired result. Considering that, the enantioseparation 
of the three compounds, was not achieved in CSP in normal elution mode, the next trial 
was carried out with reversed elution mode. 
 
Figure 11: Chromatogram obtain using Hex/IPA/DEA 90/10/0.1 (v/v/v) (blue line), 
Hex/IPA/DEA 90/10/0.05 (v/v/v) (oranje line) Hex/EtOH/DEA 96/4/0.1 (v/v/v) (yellow 
line)
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Table 14: Results of enantiomeric separation of Tramadol in normal elution mode on Cellulose-2 CSP 
Mobile Phase 
Proportion 
(v:v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
Hex/IPA/DEA 90:10:0.1** 6.761 7.39 0.725 0.886 1.222 1.003 8.337 10.263 1.131 1.623 1.435 3.019 9.543 15.131 1.55 3.044 1.964 5.529 
Hex/IPA/DEA 95:5:0.1** 8.253 9.059 1.118 1.325 1.185 0.368 11.329 14.818 1.907 2.802 1.469 3.257 17.069 31.065 3.416 7.038 2.060 7.117 
Hex/IPA/DEA 90:10:0.05** 10.459 11.141 4.311 4.657 1.080 0.924 11.974 14.242 4.527 5.573 1.231 2.754 11.617 16.793 9.859 14.698 1.491 4.104 
Hex/IPA/DEA 96:4:0.05** 7.7 8.049 1.048 1.141 1.089 0.848 10.22 11.293 1.59 1.862 1.171 1.792 13.013 13.937 2.461 2.706 1.100 1.219 
Hex/IPA/DEA 96:4:0.05***# 6.021 6.6 1.132 1.337 1.181 0.864 8.446 - 1.99 - 1.0 - 11.745 13.936 3.159 3.975 1.181 2.336 
Hex/IPA/DEA 94:6:0.05** 7.439 7.857 0.885 0.991 1.120 1.196 1.309 - 1.472 - 1.0 - 13.846 18.749 2.509 3.751 1.495 4.971 
Hex/IPA/DEA 94:6:0.05*# 12.501 12.792 1.014 1.061 1.046 0.155 16.05 - 1.585 - 1.0 - 21.827 - 2.516 - 1.0 . 
Hex/IPA/DEA 94:6: 0.1*# 12.251 12.748 0.97 1.05 1.082 0.538 16.222 - 1.608 - 1.0 - 21.843 - 2.512 - 1.0 - 
Hex/EtOH/DE
A 96:4: 0.1*** 6.139 7.632 1.19 1.723 1.448 0.323 9.014 11.743 2.215 3.188 1.439 3.134 14.514 20.055 4.15 6.116 1.474 5.89 
Hex/EtOH/DE
A 96:4: 0.1** 8.001 8.44 0.978 1.086 1.110 1.119 11.783 - 1.912 - 1.0 - 18.448 20.891 3.56 4.164 1.170 2.418 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; 
Rs: Resolution; * flow rate of 0.3 mL/min; ** flow rate of 0.5 mL/min; *** flow rate of 0.7 mL/min; # oven temperature at 27°C) 
Results and Discussion 
  
 34 
Within this elution mode many combination of mobile phase were attempted. The 
results are shown in Table 15. 
In this elution mode, the best enantioseparation and resolution were achieved to 
Tramadol (Tables 15), with Rs values higher than 1.5. 
Figure 12 presented the chromatograms of the best results using the reversed elution 
mode on Cellulose-2 CSP. The increase of H2O percentage improved the 
enantioseparation of Tramadol and O-DT, but does not improved the separation of N-DT 
enantiomers. It was tested different percentages of DEA, in order to understand how 
influenced the separation. The decrease of DEA percentage in mobile phase decreased 
the enantioseparation of the compounds. Despite the good results in the 
enantioseparation of the enantiomers the simultaneous separation of all the enantiomers 
was not achieved in this CSP, in normal and reversed mode of elution. Thus, the next 
step was to attempt a similar CSP was in normal and reversed elution modes. 
 
Figure 12: Chromatogram obtain using ACN(5mM ammonium formate):DEA/H2O 
35:0.1/65 (v/v/v) (blue line) and ACN(5mM ammonium formate):DEA/H2O 30:0.1/70 
(v/v/v) (oranje line)
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Table 15: Results of enantiomeric separation of Tramadol in reversed elution mode on Cellulose-2 CSP 
Mobile Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
ACN (5 mM 
ammonium 
formate): DEA/ H2O 
35:0.1/65* 25.8 27.275 5.745 6.131 1.067 1.486 20.222 - 4.287 - 1.0 - 8.741 9.266 1.285 1.423 1.107 0.949 
ACN (5 mM 
ammonium 
formate): DEA/ H2O 
30:0.1/70* 42.175 44.723 9.976 10.639 1.066 1.887 31.464 - 7.188 - 1.0 - 11.155 11.934 1.903 2.106 1.107 1.305 
ACN (5 mM 
ammonium 
formate): DEA/ H2O 
20:0.1/80** >60 - - 1.0 - >60 - - 1.0 - 17.398 20.062 5.153 6.094 1.183 2.318 
ACN (5 mM 
ammonium 
formate): DEA/ H2O 
25:0.1/75* 55.078 56.627 18.767 20.041 1.068 1.341 38.51 - 12.821 - 1.0 - 10.952 12.13 2.931 3.353 1.144 1.728 
EtOH (5 mM 
ammonium 
formate): DEA/ H2O 
40:0.1/60**# 39.945 - 13.199 - 1.0 - 27.702 29.979 8.847 9.657 1.092 1.221 11.56 - 3.109 - 1.0 - 
ACN:EtOH (5 mM 
ammonium 
formate):DEA/H2O 
16.36:28.63:
0.1/55*# 21.168 22.087 4.509 4.748 1.053 0.645 18.58 - 3.835 - 1.0 - 8.411 8.961 1.189 1.332 1.120 0.724 
ACN:EtOH (5 mM 
ammonium 
formate):DEA/H2O 
16.36:28.63:
0.05/55*# 17.302 17.891 3.617 3.465 0.958 0.289 8.96 - 1.312 - 1.0 - 7.513 7.886 0.939 1.035 1.102 0.31 
ACN:EtOH (5 mM 
ammonium 
formate):DEA/ H2O 
14.55:25.45:
0.05/60*# 26.491 27.487 5.819 6.076 1.044 0.474 12.059 - 2.104 - 1.0 - 9.456 10.113 1.434 1.603 1.118 0.73 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; 
Rs: Resolution; * flow rate of 0.3 mL/min; ** flow rate of 0.5 mL/min; *** flow rate of 0.7 mL/min; # oven temperature at 27°C) 
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Table 15: Results of enantiomeric separation of Tramadol in reversed elution mode on Cellulose-2 CSP (continuation) 
Mobile Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
ACN:EtOH (5 mM 
ammonium 
formate):DEA/ 
H2O 
12.73:22.27:
0.1/65**# 41.747 43.631 13.888 14.56 1.048 1.055 34.339 - 11.246 - 1.0 - 10.432 11.426 2.72 3.075 1.131 1.267 
ACN:EtOH (5 mM 
ammonium 
formate):DEA/ 
H2O 
14.54:25.46:
0.1/60*# 34.004 35.495 7.82 8.207 1.049 0.916 28.996 - 6.521 - 1.0 - 10.827 11.744 1.809 2.046 1.131 1.068 
ACN:EtOH (5 mM 
ammonium 
formate):DEA/ 
H2O 
8:32:0.1/ 
60*# 46.273 47.852 10.857 11.261 1.037 0.508 39.448 - 9.108 - 1.0 - 12.952 14.03 2.319 2.595 1.119 0.864 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; 
Rs: Resolution; * flow rate of 0.3 mL/min; ** flow rate of 0.5 mL/min; *** flow rate of 0.7 mL/min; # oven temperature at 27°C) 
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Cellulose-4 CSP (Figure 13) was selected to search the enantioseparation of the 
target compounds. The only difference between Cellulose-2 and Cellulose-4 is the 
position of substituents of aromatic ring of the carbamate. The initially tests in this CSP 
was using reversed elution mode. Table 16 presented the results of Tramadol, N-DT and 
O-DT, using ACN with ammonium formate and DEA in different proportions. 
O
OCONHR
O
OCONHR
RHNOCO
Cl
H3C
R=
  
Figure 13: Chemical Structure of Lux Cellulose-4 
The majority of mobile phases attempted presented enantioseparation of the target 
compounds individually. The best result was achieved with ACN (5mM ammonium 
formate) : DEA/H2O 35:0.1/65 as mobile phase (Figure 14), all target compounds 
presented enantioseparation but no chemoselective with Tramadol and N-DT, which is 
a good results and conditions for analyses by mass spectrometry analysers but not 
satisfactory for UV and FD detectors. For this reason, MeOH and EtOH were used 
instead of ACN. 
 
Figure 14: Chromatogram of mixture of three analytes (orange line) and of mixture of 
O-DT and Tramadol (blue line) using ACN (5 mM ammonium formate) : DEA/ H2O 
35:0.1/65 (v/v/v) as mobile phase with a flow rate of 0.5 mL/min and an oven 
temperature of 23 °C
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Table 16: Results of enantiomeric separation of Tramadol in reversed elution mode, using ACN, on Cellulose-4 CSP 
Mobile Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
50:0.1/50* 10.405 11.282 1.690 1.916 1.134 1.928 9.727 10.204 1.542 1.666 1.080 0.678 5.832 6.48 0.513 0.681 1.327 1.6 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
40:0.1/60* 17.015 18.808 3.215 3.659 1.138 2.662 18.496 19.600 3.639 3.916 1.076 1.326 6.794 7.895 0.683 0.956 1.400 2.397 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
35:0.1/65* 25.03 28.078 6.315 7.206 1.141 2.794 27.094 28.838 10.688 11.440 1.070 1.256 7.862 9.091 1.245 1.657 1.331 2.312 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
45:0.1/55* 12.665 13.847 2.252 2.556 1.135 2.149 13.557 14.032 2.48 2.671 1.077 1.101 6.2 7.046 0.592 0.810 1.368 1.733 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
45:0.1/55*# 12.708 13.82 2.262 2.547 1.126 2.068 13.291 13.928 2.411 2.574 1.068 1.003 6.272 7.072 0.61 0.815 1.336 1.666 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
45:0.08/55* 11.19 12.244 1.897 2.17 1.144 1.251 10.517 - 1.746 - 1.0 - 6.186 6.804 0.601 0.762 1.268 0.915 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
30:0.08/70* 36.931 41.52 8.213 9.358 1.139 2.842 19.545 - 3.853 - 1.0 - 7.761 8.892 0.936 1.218 1.313 0.943 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
35:0.05/65* 3.875 4.5 2.69 3.285 1.221 1.025 3.861 4.384 1.03 1.305 1.267 0.908 3.693 - 1.107 - 1.0 - 
ACN (5 mM 
ammonium formate) 
: DEA/ H2O 
30:0.05/70* 5.164 - 1.638 - 1.0 - 3.718 4.235 0.611 0.835 1.367 0.762 4.002 - 1.044 - 1.0 - 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; Rs: Resolution; * flow rate 
of 0.5 mL/min; # oven temperature at 27°C) 
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Table 17 presented the results of the separations of Tramadol, N-DT and O-DT using 
an alcohol in the mobile phase, respectively. 
According to the results presented in Table 17 and Figure 15, the best result was 
obtained using MeOH ( 5mM Ammonium formate) : DEA/ H2O 55:0.05/ 45 (v:v/v) with a 
flow rate of 0.5 mL/min and an oven temperature of 23 °C. In this mobile phase it is 
possible to observe partial separation of N-DT, baseline separation of Tramadol, but with 
retention time (RT > 50 min) and O-DT with good enantioseparation. The influence of 
amount of DEA and of ammonium formate, was also verified. The variation of 
concentration of ammonium formate did not influence the separation, but the decrease 
of DEA percentage did not help the enantioseparation of compounds, with exception of 
decrease of DEA percentage in a mobile phase with MeOH.  
 
Figure 15: Chromatogram of mixture of three analytes using MeOH (5 mM ammonium 
formate) : DEA/ H2O 55:0.05/ 45 (v:v/v) as mobile phase with a flow rate of 0.5 mL/min 
and an oven temperature of 23 °C 
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Table 17: Results of enantiomeric separation of Tramadol in reversed elution mode, using an alcohol, on Cellulose-4 CSP at a flow-rate of 0.5mL/min 
Mobile 
Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
EtOH (15 mM 
ammonium 
formate)/ H2O 
pH=8.19 
[adjusted with 
DEA] 
50/50 8.817 9.133 1.263 1.344 1.064 0.393 4.89 - 0.250 - 1.0 - 5.323 - 0.356 - 1.0 - 
EtOH (15 mM 
ammonium 
formate)/ H2O 
pH=8.03 
[adjusted with 
DEA] 
40/60 13.87 14.806 2.521 2.758 1.094 0.808 5.809 - 0.472 - 1.0 - 6.031 6.361 0.529 0.613 1.159 0.139 
EtOH (10 mM 
ammonium 
formate)/ H2O 
pH=7.96 
[adjusted with 
DEA] 
50/50 13.967 14.918 2.559 2.801 1.095 0.943 6.204 - 0.576 - 1.0 - 6.711 7.145 0.701 0.811 1.157 0.467 
EtOH (10 mM 
ammonium 
formate) : 
DEA/ H2O 
45:0.1/55 35.156 38.223 7.742 8.504 1.098 1.939 27.82 28.859 5.917 6.176 1.044 0.54 11.639 13.009 18.940 2.235 0.118 1.422 
EtOH (10 mM 
ammonium 
formate) : 
DEA/ H2O 
50:0.1/50 21.264 22.813 4.214 4.594 1.090 1.328 17.979 - 3.409 - 1.0 - 8.82 9.607 1.163 1.356 1.166 0.98 
EtOH (10 mM 
ammonium 
formate) : 
DEA/ H2O 
47:0.1/53 28.322 30.684 5.939 6.517 1.097 1.763 22.752 23.402 4.574 4.733 1.035 0.188 10.287 11.383 1.520 1.789 1.177 1.169 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; Rs: Resolution)
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Table 17: Results of enantiomeric separation of Tramadol in reversed elution mode, using an alcohol, on Cellulose-4 CSP (contituation) 
Mobile 
Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
EtOH (5 mM 
ammonium 
formate)/ H2O 
pH=7,96 
[adjusted with 
DEA] 
50/50 13.953 14.881 2.554 2.790 1.092 0.869 3.942 5.981 2.249 3.928 1.747 3.238 6.644 7.073 0.685 0.794 1.159 0.349 
MeOH (5 mM 
ammonium 
formate)/ H2O 
45/55 >60 - - - - >60 - - - - 28.199 32.814 5.75 6.877 1.196 1.777 
MeOH (5 mM 
ammonium 
formate) : 
DEA/ H2O 
50:0.1/50 >60 - - - - >60 - - - - 18.503 21.335 3.437 4.117 1.198 1.729 
MeOH (5 mM 
ammonium 
formate) : 
DEA/ H2O 
60:0.05/ 
40 30.063 32.999 6.159 6.859 1.114 1.929 16.291 - 2.88 - 1.0 - 10.698 11.816 1.548 1.814 1.172 1.192 
MeOH (5 mM 
ammonium 
formate) : 
DEA/ H2O 
55:0.05/ 
45 49.505 54.886 10.671 11.94 1.119 2.181 23.836 24.713 4.619 4.826 1.045 0.236 14.562 16.332 2.433 2.850 1.171 1.433 
MeOH (5 mM 
ammonium 
formate) : 
DEA/ H2O 
45:0.05/ 
55 49.505 54.886 10.671 11.990 1.119 2.181 23.836 24.713 4.619 4.826 1.045 0.236 14.562 16.332 2.433 2.850 1.172 1.433 
MeOH (5 mM 
ammonium 
formate) : 
DEA/ H2O 
45:0.02/ 
55 77.683 86.688 17.7 19.87 1.122 2.179 22.736 - 4.433 - 1.0 - 17.98 20.473 3.306 3.928 1.188 0.968 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; Rs: Resolution)
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The last tentative of enantioseparation of the target compounds in this mode of elution 
was to join two organic solvents, like ACN with EtOH. The results of this tentative are 
presented in Table 18. 
The join of these two solvents does not improve the enantioseparation. The best 
mobile phase was constituted with ACN:EtOH(10mM ammonium formate):DEA/ H2O in 
a proportion of  17.5:17.5:0.1/65 (v:v:v/v) with a flow rate of 0.5 mL/min and an oven 
temperature of 23 °C (Figure 16). Tramadol and O-DT presented good resolution (Rs > 
1.5) but N-DT presented only partial enantioseparation. Due these reasons, this elution 
mode was abandoned and the further tests were made in normal elution mode. 
 
Figure 16: Chromatogram of mixture of three analytes using ACN:EtOH (10 mM 
ammonium Format):DEA/ H2O 17.5:17.5:0.1/65 (v:v:v/v) as mobile phase with a flow 
rate of 0.5 mL/min and an oven temperature of 23 °C 
Many different mobile phases were evaluated on Cellulose-4 CSP in normal elution 
mode. Table 19 shows the results of this elution mode for Tramadol, N-DT and O-DT.  
Normal elution mode allowed enantioseparation with high resolutions (1.848 < Rs < 
4.161) and good selectivity (1.187 < α < 1.344). EtOH and IPA were used as organic 
modifier and DEA as ionic suppressor.  The enantio and chemoselective were achieved 
using Hex/EtOH/DEA as mobile phase, in a proportion of 96:4:0.1 (v:v:v), and in a flow 
of 0.7 mL/min. The chromatogram presented in Figure 17 shows the excellent 
chromatographic parameters. These conditions were used to validate the 
chromatographic method for further quantification of Tramadol and its metabolites N-DT 
and O-DT in influent and effluents of WWTP.
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Table 18: Results of enantiomeric separation of Tramadol and its metabolites in reversed elution mode, using a mixture  of organic solvents, on 
Cellulose-4 CSP, at a flow-rate of 0.5 mL/min 
Mobile Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) 
K1 K2 α Rs 
ACN:EtOH (10 
mM ammonium 
formate):DEA/ 
H2O 
20:20:0.1/65 24.888 27.49 5.13 5.771 1.125 2.166 15.657 16.156 2.856 2.979 1.043 0.114 9.445 10.933 1.326 1.693 1.277 1.876 
ACN:EtOH (10 
mM ammonium 
formate):DEA/ 
H2O 
17.5:17.5:0.1
/65 40.319 45.116 8.912 10.091 1.132 2.69 22.962 24.096 4.645 4.923 1.060 0.36 12.481 14.837 2.068 2.647 1.280 2.619 
ACN:EtOH (10 
mM ammonium 
formate):DEA/ 
H2O 
21:9:0.1/60 20.287 22.441 4.033 4.567 1.132 1.966 13.977  - 2.467 - 1.0 - 8.374 9.61 1.077 1.384 1.285 1.809 
ACN:EtOH (10 
mM ammonium 
Format):DEA/ 
H2O 
31.5:31.5: 
0.1/55 >40 - - - - 30.238 31.893 6.429 6.836 1.063 0.272 14.57 17.949 2.58 3.410 1.322 3.188 
ACN:EtOH (5 
mM ammonium 
formate):DEA/ 
H2O 
35:20:0.1/ 
45 11.801 12.716 1.939 2.166 1.117 1.529 12.039 12.579 1.959 2.092 1.068 0.719 6.242 6.844 0.554 0.704 1.271 1.144 
ACN:EtOH (5 
mM ammonium 
formate):DEA/ 
H2O 
28.6:14.5: 
0.1/55 21.105 23.368 4.168 4.722 1.133 2.417 21.252 22.548 4.244 4.563 1.075 1.083 7.901 9.091 0.949 1.243 1.310 2.064 
ACN:EtOH (5 
mM ammonium 
formate):DEA/ 
H2O 
25.5:14.5: 
0.1/60 31.479 35.432 6.697 7.664 1.144 2.583 30.928 33.079 6.539 7.063 1.080 1.443 9.428 10.946 1.305 1.676 1.284 2.691 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: Separation Factor; 
Rs: Resolution) 
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Table 19: Results of enantiomeric separation of metabolites of Tramadol in normal elution mode on Cellulose-4 CSP 
Mobile 
Phase 
Proportion 
(v/v) 
Tramadol N-DT O-DT 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
RT 1 
(min) 
RT 2 
(min) K1 K2 α Rs 
Hex/IPA 90/10* 9.206 9.839 0.185 0.266 1.438 0.856 NT NT NT NT NT NT NT NT NT NT NT NT 
Hex/IPA/DEA 90/10/0.1* 6.639 7.19 0.278 0.384 1.381 1.238 NT NT NT NT NT NT 10.385 10.907 0.999 1.111 1.112 1.051 
Hex/IPA/DEA 90/10/0.1*# 6.482 7.167 0.241 0.367 1.523 1.111 NT NT NT NT NT NT 10.38 10.97 0.973 1.093 1.123 1.278 
Hex/IPA/DEA 92/8/0.1* 6.923 7.984 0.675 0.931 1.379 1.122 NT NT NT NT NT NT 12.616 18.667 2.052 2.306 1.124 1.19 
Hex/IPA 
/DEA 94/6/0.1* 7.41 8.699 0.727 1.104 1.519 2.723 NT NT NT NT NT NT 16.137 17.523 2.903 3.238 1.115 1.281 
Hex/IPA 
/DEA 96/4/0.1* 7.217 8.766 0.747 1.122 1.502 2.737 NT NT NT NT NT NT 19.384 21.539 3.694 4.215 1.141 1.277 
Hex/EtOH/D
EA 90/10/0.1* 6.118 6.653 0.491 0.622 1.267 1.687 7.486 8.00 0.822 0.948 1.153 1.397 8.033 9.004 0.958 1.194 1.246 2.424 
Hex/EtOH/D
EA 94/6/0.1* 6.944 7.672 0.658 0.833 1.266 2.068 9.137 9.948 1.181 1.373 1.163 1.828 11.354 13.042 1.712 2.115 1.235 3.226 
Hex/EtOH/D
EA 98/2/0.1* 9.415 11.165 1.308 1.417 1.083 4.886 14.757 16.864 2.538 3.043 1.199 3.112 ND ND ND ND ND ND 
Hex/EtOH/D
EA 95/5/0.1* 7.112 7.881 0.706 0.891 1.262 1.365 9.672 10.635 1.320 1.551 1.175 1.571 12.747 15.537 2.058 2.727 1.325 3.075 
Hex/EtOH/D
EA 95/5/0.1** 5.083 5.605 0.696 0.870 1.250 1.258 6.878 7.58 1.295 1.529 1.181 1.495 9.02 11.017 2.010 2.676 1.331 2.923 
Hex/EtOH/D
EA 96/4/0.1* 7.592 8.131 0.769 0.895 1.164 1.953 10.729 11.868 1.500 1.766 1.177 1.805 15.511 18.619 2.615 3.339 1.277 3.416 
Hex/EtOH/D
EA 96/4/0.1** 5.398 5.95 0.742 0.920 1.240 2.159 7.536 8.369 1.432 1.700 1.187 1.848 10.771 13.413 2.476 3.328 1.344 4.161 
(RT 1: Retention time of enantiomer 1; RT 2: Retention time of enantiomer 2; K1: Retention Factor of enantiomer 1; K2: Retention Factor of enantiomer 2; α: 
Separation Factor; Rs: Resolution; * flow rate of 0.5 mL/min; ** flow rate of 0.7 mL/min; # oven temperature of 27 °C, NT: Not tested; ND: Not detected) 
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Figure 17: Chromatogram using Hex/EtOH7DEA 96/4/0.1 (v/v/v) with a flow of 0.7 
mL/min as mobile phase 
 
3.2. Solid-phase extraction optimization 
The best conditions for retention of target compounds in the SPE procedure was 
established with ultrapure water as matrix.  
The results of the different SPE procedures are after injection and comparing with 
standards of 1 µg/mL of the mixture of three analytes, are presented in Table 20, the 
numeration of the procedure agrees with procedure described in Table 9 (section 2.4.1., 
page 22) 
Table 20: Recovery of each SPE procedure 
Pr
oc
ed
ur
e 
C
ar
tr
id
ge
 Recovery (%) 
Pr
oc
ed
ur
e 
C
ar
tr
id
ge
 Recovery (%) 
Tramadol N-DT O-DT Tramadol N-DT O-DT 
E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 
1 MCX 34 36 34 35 30 51 7 HLB 34 42 27 24 20 27 
2 MCX 44 48 23 26 23 52 8 MCX 66 65 54 50 52 46 
3 MCX 20 20 19 19 25 12 9 MCX 79 80 82 79 84 69 
4 MCX 23 22 22 22 30 20 10 MCX 76 78 79 79 74 77 
5 MCX 60 60 90 98 78 60 11 MCX 70 70 76 69 69 71 
6 MCX 38 38 52 53 43 29 12 MCX 105 102 77 82 106 59 
(Enantiomer 1 and 2: the first and second enantiomer eluted, respectively) 
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Procedure 12 (Table 20) presented the best recovery of the compounds, this 
procedure were performed using Oasis® MCX cartridge 150 mg 6cc. This procedure 
was selected procedure for applying to WWTP sample (Figure 18). 
 
Figure 18: Optimized SPE procedure 
The SPE procedures were performed in a sample without spiked and with a spiked 
sample, in triplicate, with a mixture of Tramadol, N-DT and O-DT with a racemic 
concentration of 1 µg/mL. 
The recovery of each compound is calculated by the formula previously mentioned, 
and in order to quantify only the compounds and not the interfering the area of peak in 
spiked matrix is calculated by the following formula: ܣ ௥௘௔௟ (௣௘௔௞ ௜௡ ௦௜௣௞௘ௗ ௠௔௧௥௜௫) =
 ܣ௣௘௔  ௢௙ ௦௣௜௞௘ௗ ௦௔௠௣௟௘ −  ܣ௣௘௔௞ ௢௙ ௡௢௡௦௣௜௞௘ௗ ௦௔௠௣௟௘. The results is presented in Table 21. 
Table 21: Recovery in WWTP sample 
Analyte Tramadol N-DT O-DT 
Enantiomer 1 2 1 2 1 2 
Recovery (%) 81 88 69 64 81 74 
(Enantiomer 1 and 2: the first and second enantiomer eluted, respectively) 
 
3.3. Method validation 
According to the International Conference in Harmonization Q2B (95) the goal of the 
validation of an analytical method is to demonstrate that the method is suitable to the 
objective required. In order to proceed with the validation of the LC-FD method 
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developed for the quantification of the enantiomers of Tramadol and its metabolites the 
following parameters were considered: selectivity; linearity; accuracy; precision (intra-
day and inter-day), detection limit, and quantification limit. Every parameter of the 
validation has specific definition and objective. 
3.3.1. Selectivity 
Selectivity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present, as impurities, degradation products, 
matrix interferences, etc. To assess the selectivity of the developed method and given 
its importance in environmental studies due to the potential presence of other substances 
in the matrix. The protocol followed included the analysis of a synthetic WWTP sample, 
previously treated by SPE procedure. The chromatogram obtained is represented in 
Figure 19, under the optimized chromatographic conditions referred in section 3.1.2. 
To guarantee the selectivity the matrix spiked with the mixture of Tramadol, N-DT and 
O-DT were also analyzed, each one in a final concentration of 410 ng/mL of the racemic 
mixture, Figure 20 represents the chromatogram obtained for the matrix spiked. Figure 
21 represents the chromatogram obtained for mix of three compounds in solvent 
(Hex/EtOH 8:2 (v:v)), in order to understand if the interferences of the synthetic 
influences in the separation of the compounds. The comparison between the three 
chromatograms presented certificates that the synthetic influent matrix does not 
represent any interference. 
 
Figure 19: Chromatogram of Synthetic Influent; mobile phase: Hex/EtOH/DEA 96:4:0,1 
(v:v:v) ; flow rate = 0.7 mL/min; column oven temperature = 23 ºC 
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Figure 20: Chromatogram of mixture of compounds, at 410 ng/mL of racemic mixture, 
spiked in Synthetic Influent; mobile phase: Hex/EtOH/DEA 96:4:0.1 (v:v:v) ; flow rate = 
0.7 mL/min; column oven temperature = 23 ºC 
 
Figure 21: Chromatogram of mix of compounds in solvent in racemic concentration of 
410 ng/mL; mobile phase: Hex/EtOH/DEA 96:4:0.1 (v:v:v) ; flow rate = 0.7 mL/min; 
column oven temperature = 23 ºC 
3.3.2. Linearity 
The linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the concentration (amount) of analyte in the 
sample. The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. To an analytical LC method to be considered able to 
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quantify analytes there must be a linear relation between the concentration and the 
absorbance of the chromatographic peaks within the linear range of the procedure. In 
the linearity assay of this work was used a concentration range considering five different 
concentration levels. According ICH (95) a minimum of five different concentration levels 
is required to demonstrate linearity within the linear range. The results should be 
statistically manipulated with appropriate methods such as the linear regression. In order 
to construct the calibration curves to each compound were prepared the racemic 
concentrations of 70 ng/mL, 140 ng/mL, 210 ng/mL, 280 ng/mL, 350 ng/mL, 420 ng/mL 
and 480 ng/mL spiked in synthetic wasterwater in triplicate and each one was injected 
and analyzed in duplicate. To the calibration curve was used 5 concentration, different 
for each compound, and in some cases, for each enantiomer of the same compound. To 
the calibration curve of enantiomers of Tramadol and N-DT were used a range of nominal 
concentration between 35 and 210 ng/mL and to the calibration curve of each enantiomer 
of O-DT were used a range of 70 to 245 ng/mL. 
The calibration curves as well as the curve equations are represented in figures 22 - 
27, for enantiomer 1 of T, enantiomer 2 of T, enantiomer 1 of N-DT, enantiomer 2 of N-
DT, enantiomer 1 of O-DT and enantiomer 2 of O-DT respectively. The correlation 
coefficients were always higher than 0.99. 
 
 
Figure 22: Calibration curve of enantiomer 1 of Tramadol 
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Figure 23: Calibration curve of enantiomer 2 of Tramadol 
 
Figure 24: Calibration curve of enantiomer 1 of N-DT 
 
Figure 25: Calibration curve of enantiomer 2 of N-DT 
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Figure 26: Calibration curve of enantiomer 1 of O-DT 
 
Figure 27: Calibration curve of enantiomer 2 of O-DT 
3.3.3. Accuracy  
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. The accuracy of an analytical method expresses 
the concordance between a value determined by the analytical method and the real value 
of analyte in the sample. Accuracy must be evaluated with a minimum of three different 
concentration levels in triplicate (nine determinations) according Q2B guideline (95) and 
calculated by the relation between the concentration obtained by the peak area of the 
standards and the nominal concentrations. The following racemic concentrations were 
used: 150 ng/mL, 300 ng/mL and 410 ng/mL. Results for the accuracy assay are exhibit 
in Table 22. ICH (95) recommends accuracy values for pharmaceutical compounds 
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between 70% and 130%.  Through the Table 22 it is possible see that the method is 
accurate, once the values are within the aforementioned range. 
 
3.3.4. Precision  
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling 
of the same homogeneous sample under the prescribed conditions. The precision of an 
analytical procedure is usually expressed as the variance, standard deviation or 
coefficient of variation of a series of measurements. In the validation of this work the 
method precision was evaluated considering the parameters repeatability (intra-assay 
precision) and intermediate precision (inter-assay precision) and the values expressed 
in % of relative standard deviation (RSD). Following ICH (95) recommendations both 
precision parameters were calculated using nine determinations. Consequently, three 
different concentrations were prepared, each one in triplicate. Intra-day precision was 
studied by the analyses of the nine determinations, all performed in the same day with 
similar work conditions (operator, equipment, temperature and humidity). Inter-day 
precision was studied by the analyses of the nine determinations performed along three 
different days, maintaining the conditions operator and equipment and modifying the 
conditions temperature and humidity. Table 22 presents the values of RSD obtained for 
repeatability and intermediate precision.  It is also a precise method. 
 
3.3.5. Recovery  
 The recovery rate refers to the extraction ability of the method and relates to the 
fraction of analyte added to a test sample. The percentage of recovery was obtained 
comparing the peak area ratio of the compound after a SPE procedure to the ones 
prepared at the same concentrations in solvent. Three different concentrations were 
used and prepared each one in triplicate, as done before for accuracy and precision 
determination. Table 22 presents the values of percentage of recovery obtained for each 
enantiomer of Tramadol and its metabolites.  
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Table 22: Recovery, accuracy, intra- and inter-day precision of each enantiomer 
Analyte 
Nominal 
Concentration 
(ng/mL) 
E 
1st Day 2nd Day 3rd Day Inter-
Day 
RSD 
(%) 
Recovery 
(%) Accuracy 
(%) 
RSD 
(%) 
Accuracy 
(%) 
RSD 
(%) 
Accuracy 
(%) 
RSD 
(%) 
Tramadol 
75 
1 89.6 7.7 88.5 4.9 94.3 3.1 6.5 87.1 
2 90.6 8.3 91.4 3.7 93.3 5.9 6.4 88.9 
150 
1 80.1 4.6 80.6 1.6 82.1 6.5 4.9 78.4 
2 81.0 6.7 80.4 0.3 82.9 5.8 5.4 78.3 
205 
1 105.6 1.0 82.2 8.0 97.9 8.5 12.5 97.8 
2 70.3 1.1 84.0 3.8 90.0 8.4 11.7 83.2 
N-DT 
75 
1 99.1 8.2 82.0 8.8 105.7 3.5 11.7 99.2 
2 114.1 8.8 91.2 3.9 100.0 8.9 11.7 99.4 
150 
1 98.3 1.7 91.9 6.2 97.5 6.1 5.8 97.6 
2 87.8 5.6 81.3 1.5 90.6 6.7 6.8 88.2 
205 
1 77.0 6.3 85.6 4.0 105.4 7.9 16.7 85.9 
2 79.4 4.9 89.6 3.7 108.7 7.4 16.3 89.8 
O-DT 
75 
1 94.9 5.0 92.5 8.2 96.9 4.5 14.8 72.2 
2 96.0 6.8 97.1 8.9 97.5 9.2 9.5 83.6 
150 
1 97.0 9.9 93.2 5.0 96.3 7.8 10.6 87.4 
2 99.9 4.6 98.5 7.2 99.4 3.6 5.9 98.1 
205 
1 81.7 7.0 90.0 4.5 97.9 3.8 14.9 82.0 
2 90.2 5.9 95.6 6.3 106.3 8.9 14.5 92.2 
(E:Enantiomer) 
3.3.6. Detection Limit (DL) and Quantification Limit (QL)  
The detection limit (DL) of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily quantified as an exact 
value and the quantification limit (QL) is the lowest amount of analyte in a sample which 
can be quantitatively determined with suitable precision and accuracy. In this work the 
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detection and quantification limits were calculated by the signal/noise ratio. According 
ICH Q2B (95) the determination of the signal-to-noise ratio is performed by comparing 
measured signals from samples with known low concentrations of analyte with those of 
blank samples and establishing the minimum concentration at which the analyte can be 
reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally considered 
acceptable for estimating the DL. A signal-to-noise ratio of 10:1 is suitable for estimating 
the QL. Table 23 summarizes the instrumental DL and QL values of each enantiomer of 
the different compounds in solvent. Figure 28 represents two stacked chromatograms 
corresponding to the concentration of instrumental DL (orange line), and instrumental 
QL (green line).  
Table 23: Detection and Quantification limits of each enantiomer of the analytes 
Analyte Enantiomer DL (ng/L) QL (ng/L) 
Tramadol 
1 8 28 
2 8 28 
N-DT 
1 8 28 
2 8 28 
O-DT 
1 20 56 
2 20 56 
 
 
Figure 28: Chromatogram of the detection limite (orange line) and quantification limite 
(green line) 
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3.4. Application of developed LC-FD method in WWTP samples 
The method developed and validated was used to quantify sample from effluent 
and influent of WWTP. After collected the samples, acidification and the subsequent 
process SPE, the samples were analyzed using the optimized conditions previously 
established. Table 24 presents the results obtained in influent and effluent of WWTP of 
Parada, North of Portugal. 
Table 24: Concentration of analytes present in samples collected 
Sample 
nº Sample 
Concentration (ng/L) 
Tramadol N-DT O-DT 
E1 E2 E1 E2 E1 E2 
1 
Effluent ND QL QL QL ND ND 
Influent ND ND ND ND ND ND 
2 
Effluent ND ND ND ND ND ND 
Influent ND 60.6 QL QL ND ND 
3 
Effluent 235.8 118.7 QL 43.7 60.8 57.7 
Influent 357.9 233.6 QL 63.9 69.7 86.7 
4 
Effluent 325.1 314.9 QL 62.1 71.6 95.4 
Influent 350.0 233.8 QL 72.7 69.5 106.7 
(<QL: under quantification limit; ND: not detected; E1 and E2 are the first and second enantiomers 
eluted, respectively) 
Crossmatch with standards was performed to certify presence of analytes in the 
samples.  
The results from Table 24 shows that the target compounds were not quantified in 
the effluent and in influent in first day of sample collection, expect the second enantiomer 
of Tramadol in the sample collected in the afternoon (60.6 ng/L).  
Regarding samples collected on the day 2, all enantiomers of the compounds could 
be quantified, except the enantiomer 1 of N-DT, which were under QL. Although with 
some interfering providing by the matrix, it is possible see the presence of each 
enantiomer of each compound. The chromatograms presented in Figure 29 the samples 
collected in morning of day 2 and in Figure 30, samples collected in afternoon.  
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Figure 29: Chromatogram of sample 3, influent sample (orange line) effluent sample 
(green line) 
 
Figure 30: Chromatogram of sample 4, influent sample (orange line) effluent sample 
(green line) 
Chromatograms of the cross match test with an overlap of sample chromatogram 
are presented in Figure 31, 32, 33 and 34.  
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Figure 31: Chromatogram of efluent sample nº 3 (green line) and crossmatch test with 
the sample (orange line) 
 
 
 
Figure 32: Chromatogram of influent sample nº 3 (green line) and crossmatch test 
with the sample (orange line) 
Results and Discussion 
  
 58 
 
Figure 33: Chromatogram of efluent sample nº 4 (green line) and crossmatch test with 
the sample (orange line) 
 
Figure 34: Chromatogram of influent sample nº4 (green line) and crossmatch test with 
the sample (orange line) 
The presence of interfering in the sample matrix difficult the quantification of the 
analytes. Although this difficult, in the case of Tramadol the interfering appears between 
the enantiomers and in the case of O-DT the interfering affect the quantification of 
second the enantiomer 2, it was possible to predict the concentration of the enantiomers 
of Tramadol, N-DT and O-DT in WWTP.  
Results and Discussion 
  
 59 
Table 25 present results of EF, the fraction can only range from 0 to 1.0, if EF = 
0.5 means that is present in racemic mixture. 
Table 25: EF of analytes in the samples 
Sample 
nº Sample 
EF 
Tramadol N-DT O-DT 
E1 E2 E1 E2 E1 E2 
3 
Effluent 0.67 0.33 - ≈1.00 0.51 0.49 
Influent 0.61 0.39 - ≈1.00 0.45 0.55 
4 
Effluent 0.51 0.49 - ≈1.00 0.43 0.57 
Influent 0.60 0.40 - ≈1.00 0.39 0.61 
(E1: enantiomer 1; E2: enantiomer 2) 
Through the values of EF it is possible see if the analyte are present in the 
racemic mixture. The second enantiomer eluted of N-DT present a value of EF next to 
1.0, once the first enantiomer  was under QL. Tramadol were presented in the samples 
in proportion next to racemic mixture, but is evident that enantiomer 1 were present in a 
major concentration. O-DT is the analyte which is mostly very close to the value 0.5, 
what revel that this analyte are presented in proportion next to racemic mixture. . 
Table 26 shows the results of DRE, through this value is possible predict if the 
removal of pollutants. 
 
Table 26: DRE values of the analytes in the samples 
Sample nº 
DRE (%) 
Tramadol N-DT O-DT 
E1 E2 E1 E2 E1 E2 
3 65.9 50.8 - 68.4 87.2 66.6 
4 92.9 134.7 - 85.4 103.0 89.4 
(E1: enantiomer 1; E2: enantiomer 2) 
In the first day the compounds were not found in all the samples and are not 
possible calculate this value, but it is possible using the samples of second day. 
According to these results it is possible conclude that in a majority of the times, the 
elimination treatment is inefficient (DRE<60%). 
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A LC-FD method was developed and validated for the identification and 
quantification the enantiomers of Tramadol and its primary metabolites, N-DT and O-DT 
in influent and effluent of WWTP. Search for ideal CSP and mobile phase conditions for 
enantioseparation of all enantiomers was allowed the further validation and quantification 
of all target compounds. The optimized conditions were achieved with Lux Cellulose-4 
as CSP and Hex/EtOH/DEA 96/4/0.1 (v/v/v) as mobile phase in an isocratic mode and a 
flow of 0.7 mL/min. The separation of all enantiomers (six compounds) has been 
obtained with a run time shorter than 15 minutes, with good resolution, Rs>1.5, and 
enantioselectivity, α>1.1.  
SPE procedure for pre-concentration and cleanup using MCX cartridge allowed 
quantification in 250 mL of sample volume.   
The validated method demonstrated selectivity, with good linearity (r2>0.99) and 
demonstrated precision (intra-day: 0.3<RSD<13.8; inter-day: 5.4<RSD<16.7), in the 
racemic range of 56 ng/L – 384 ng/L. The values of accuracy and precision for the quality 
control of the highest concentration of O-DT it should be adjusted. The QL achieved were 
28 ng/L for each enantiomer of Tramadol and of N-DT and 56 ng/L for each enantiomer 
of O-DT.  
A several sample from effluent and influent WWTP were analysed and the 
compounds were detected in a concentration range below to QL to 325.1 ng/L and 357.9 
ng/L, respectively. Enantiomers of Tramadol and O-DT revels an EF next to racemic 
mixture (EF≈0.5), due the enantiomer 1 of N-DT presented in a concentration under of 
QL, the EF is approximately to 1.0. 
Samples 3 present a range of DRE between 50.8% and 87.2%, the sample 4 
present a range of DRE between 85.4% and 134.7%.  
As future perspectives it would be interesting to investigate the elution order of 
the enantiomers in order to confirm which enantiomer is at higher concentration.  The 
enantio ecotoxicological effects of Tramadol and its metabolites would be also important 
for further environmental risk evaluation studies. Increasing of sample analyses with 
different WWTP form different regions are also important to support the data achieved in 
this work.  
HPLC enantioseparation of tramadol and metabolites: method validation and 
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